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ABSTRACT
We previously demonstrated that embryonic stem (ES) cells over-expressing
tissue inhibitor of metalloproteinase-1 (TIMP-1) have increased potential to engraft and
differentiate into cardiac myocytes following transplantation into the infarcted heart.
However, the ability of TIMP-1 to activate endogenous stem cells and enhance their
differentiation into cardiac regenerative cell types is still unknown. We postulate that
TIMP-1 may additionally activate a stem cell population that enhances cardiac cell type
differentiation in the infarcted myocardium. To prove this hypothesis, we isolated c-kit+ve
cells from four weeks old C57BL/6 mice and cultured them in vitro in presence of ES
conditioned media (ESCM), ES-TIMP-1-CM or TIMP-1. Our immunostaining data
validate the existence of a novel CD63+ve/c-kit+ve cells. When treated with TIMP-1, these
cells showed significantly (p<0.05) increased proliferation and differentiation into cardiac
myocytes, vascular smooth muscle cells, and endothelial cells. Western blot analysis
revealed significantly (p<0.05) increased expression of CD63, phosphorylated and total
β-catenin proteins. Furthermore, our RT-PCR data showed increased cardiac gene
expression (GATA-4, Mef2C, and Nkx-2.5) when compared to ESCM and control cells.
Based on the in vitro findings, we investigated the effect of intramyocardial delivery of
TIMP-1 on endogenous CD63+ve/c-kit+ve cells following myocardial infarction (MI).
C57BL/6 and TIMP-1 KO mice underwent coronary artery ligation followed by
intramyocardial delivery of 20µl of culture media (CC), ESCM, ES-TIMP-1-CM or TIMP1. Subsequent immunohistochemistry analysis demonstrated the presence of a
CD63+ve/c-kit+ve cell population within the peri-infarct area and confirmed intramyocardial
delivery of ES-TIMP-1-CM or TIMP-1 significantly (p<0.05) enhanced their proliferation.
iii

Percentage of CD63+ve/c-kit+ve cells was significantly (p<0.05) lower in TIMP-1 KO mice
compared to C57BL/6 animals. RT-PCR analysis revealed TIMP-1 KO animals
expressed significantly less CD63 and TIMP-1 mRNAs compared to C57BL/6 mice.
Activated CD63+ve/c-kit+ve cells were also able to differentiate into major cardiac cell
types as previously shown in vitro. The differentiation potential of these cells was
however higher in C57BL/6 mice compared to TIMP-1 KO mice. We also demonstrate
that CD63+ve/c-kit+ve cells differentiation is regulated by CD63/β-catenin pathway in vivo.
Additionally, we provide evidence that TIMP-1 protects the heart from adverse cardiac
remodeling through inhibition of cardiac apoptosis and fibrosis leading to significantly
(p<0.05) improved contractile function. Collectively, our data show TIMP-1 plays a dual
protective role in the MI heart. It activates a unique stem cell population, CD63 +ve/ckit+ve, which proliferates and differentiates into functional myocytes, smooth muscle cells
and endothelial cells mediated through CD63/β-catenin pathway. TIMP-1 also protects
the heart from adverse cardiac remodeling. Increased cardiac regeneration and
inhibition of adverse cardiac remodeling consequently lead to restored cardiac function.
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CHAPTER ONE: INTRODUCTION
MI Prevalence and Epidemiology
Myocardial infarction (MI) is a major health threat in the United States and other
western countries. According to the American Heart Association (AHA) statistics for
2014, more than 620,000 Americans will be hospitalized for an MI or coronary heart
disease (CHD) and ~295,000 will have a recurrent attack. In terms of mortality rate,
approximately every 34 seconds, 1 American has an MI, and approximately every 2
minutes, an American will die of one (30). The incidence of MI is dependent on
predisposing risk factors including: hypertension, diabetes mellitus, tobacco use,
hyperlipidemia and family history of CHD (30). Any risk factor, if present, doubles the
relative risk of developing atherosclerotic coronary artery disease. Currently used
medications have significantly improved patients quality of life; however, these therapies
are unable to prevent future episodes of MI, and mortality rate is still at record high (30).
Therefore, finding alternative therapies with better short-term and long-term outcomes
for MI patients is still at the forefront of medical research.

Myocardial Infarction Pathophysiology
Atherosclerotic plaque rupture in the main arteries of the left ventricle blocks
blood and nutrient supply to the myocardium, leading to ischemia and MI (6; 32).
Prolonged ischemia results in myocardial remodeling, which includes cardiac cell loss,
generation of fibrotic scar tissue, cardiac myocyte hypertrophy and left ventricular
dilation (2-4; 6). Necrosis and apoptosis are distinct forms of cell death, both occurring
in ischemic heart, although in the first 24 h following infarction, apoptosis is the main
form of cell death observed (8; 11). It is a highly orchestrated programmed cell death
1

characterized by cell cytoskeleton network rupture, leading to cytoplasmic membrane
breakage, cell shrinkage, and DNA fragmentation (8; 11). Cardiac myocyte apoptosis is
mediated by two distinct pathways; extrinsic and intrinsic (9). Extrinsic pathway is
triggered by extracellular death ligands such as FAS, tumor necrosis factor (TNF)-α,
and TRAIL, while intrinsic pathway is mediated through multiple Caspases (9).
Cardiac myocyte apoptosis in the infarct and peri-infarct area activates cardiac
fibroblasts, which are the main cellular modulators of cardiac fibrosis. They control extra
cellular matrix (ECM) turn over through secretion of matrix metalloproteinases (MMPs),
otherwise

called

Matrixins,

and

their

direct

inhibitors;

tissue

inhibitor

of

metalloproteinases (TIMPs) (19; 22; 33; 38). Imbalance between TIMPs and MMPs
expression has been documented in MI and is known to precipitate collagen deposition
in the interstitial and vascular spaces, leading to stiffening of the left ventricle, fibrosis
and cardiac dysfunction (7; 12; 21). Optimal contractile function relies on the integrity of
the syncytial myocardium which contracts rhythmically during each cardiac cycle to
pump the blood out of the cardiac chambers. It is then inevitable that death of cardiac
cells and accumulation of stiff collagen deposits within the infarct area would
dramatically impact contractile function, eventually leading to heart failure (6; 32).

Cell Transplantation in the Infarcted Myocardium
Cell transplantation therapies to replace dead heart cells and to prevent adverse
cardiac remodeling following MI have been extensively investigated. Such cells include
skeletal myoblasts, neo-natal and adult cardiac myocytes, human umbilical cord blood
cells (UCBCs), endothelial progenitor cells (EPCs), embryonic stem cells (ESCs, bone
marrow stem cells (BMSCs), mesenchymal stem cells (MSCs), induced pluripotent stem
2

cells (iPSCs) and cardiac stem cells (CSCs) (1; 5). Unequivocally, transplanted cells
showed some regenerative capabilities, however, cell survival rate and differentiation
were limited post-transplantation (1; 5; 27; 28). Furthermore, ESCs transplantation
involves immune response, teratoma formation and ethical concerns. iPSCs and
BMSCs on the other hand have limited engraftment and may induce tumorigenesis (1).
Additionally, MSCs were shown to induce bone formation which greatly interferes with
the myocardium contractility (1). In light of all these limitations, it is imperative to identify
ways to improve existent cell therapies or identify a new cell population for cardiac
regeneration.
One very promising characteristic of transplanted cells is their ability to influence
injured myocardium through paracrine mechanisms. Indeed, many factors released
from these cells have been demonstrated to boost cardiac cell self-renewal [(Insulin
Growth Factor (IGF), Hepatic Growth Factor (HGF) and Stem Cell Factor (SCF)],
neovascularization [Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth
Factor-9 (FGF-9)], and inhibition of adverse cardiac remodeling [Tissue Inhibitor of
Metalloproteinases-1 (TIMP-1)] (17; 21; 36; 37). Therefore, direct delivery of factors
released by stem cells to repair the damaged myocardium opens a new avenue for
cardiac regeneration.

Endogenous Cardiac Stem Cells
The identification of cardiac stem cells (CSCs) greatly challenged the belief that
the heart is a post mitotic organ, therefore increasing enthusiasm among scientific
community in their quest to repair the damaged heart. CSCs have been localized
throughout the myocardium in clusters called niches (29). They were isolated from the
3

postnatal and adult human hearts and other mammalian species (1; 23; 29; 34). They
exhibit capacity to self-renew and differentiate into cardiomyocytes, smooth muscle
cells, and endothelial cells in appropriate conditions (1; 23; 29; 34). Different subpopulations of CSCs have been identified based on extra cellular markers, such as side
population (SP) cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardiosphere cells,
Isl1+ve cells, and c-kit+ve cells, which are still the most abundant and most extensively
characterized CSCs (1; 5; 29). CSCs are believed to participate in cardiac cell turn over
and homeostasis in the healthy and injured organ. However, the reported rate of
myocyte regeneration following MI is rather low; suggesting a limited regenerative
potential of these resident stem cells (1; 5; 18; 27; 28). Therefore, identifying
mechanisms to boost endogenous CSCs activation and participation in cardiac repair
following MI appears as the most promising strategy for MI patients.

TIMP-1 in Cardiac Remodeling
Following MI, a maladaptive cardiac remodeling takes place leading to
decreased cardiac performance. The gross pathological changes involved in cardiac
remodeling include massive cardiac myocyte cell loss through apoptosis, increased
infiltration of collagen fibers throughout the infarct zone (fibrosis) and cardiac myocyte
hypertrophy leading to deregulated contractile function (2; 3). Cardiac fibroblasts, the
main cellular modulators of cardiac fibrosis, lead to overstimulation of MMPs and
downregulation of their direct inhibitors TIMPs (19; 22; 33; 38). MMPs are a family of
endopeptidases which play a role in aberrant production of ECM proteins leading to
adverse

ventricular

architecture

post-MI

(31;

38).

Tissue

inhibitors

of

metalloproteinases 1 to 4 (TIMPs 1-4) are endogenous protease inhibitors of MMPs (31;
4

38). TIMPs non-covalently bind the active site of pro-MMP, preventing its activation (31;
38).

In the heart, decreased expression of TIMP-1 was reported following MI,

correlating with enhanced expression of both MMP-2 and 9 (14; 22; 38). Additionally, up
regulation of TIMP-1 in the MI heart by direct delivery of TIMP-1 protein or vector to the
peri-infarct area has demonstrated decreased overall infarct size and infiltrated fibrosis
(20). TIMP-1 has additionally been shown to be anti-apoptotic in cardiac and noncardiac cell lines (12; 21; 25; 26). Based on these reported beneficial effects, we
generated embryonic stem (ES) cells overexpressing TIMP-1 factor (ES-TIMP-1 cells).
When transplanted to the MI heart, these cells demonstrated limited engraftment to the
host myocardium; however, collected data showed a significant decrease in adverse
cardiac remodeling parameters as well as improved functional capacity of the heart
(19). Whether the reported beneficial effects are the result of TIMP-1 released by
transplanted cells alone or other factors also released by these cells remains obscure.

TIMP-1 in Cardiac Differentiation
According to previous studies, ~ 10 % of transplanted stem cells survive in the
host milieu following transplantation (5; 23; 34). Consequently, limited cardiac myocyte
differentiation is reported from these cells (1; 20; 34). Therefore, efficacy of cell
transplantation therapy for myocardial regeneration remains a major challenge. Multiple
attempts were made to improve aforementioned statistics using various growth factors,
such as vascular endothelial growth factor (VEGF), transforming growth factor -2
(TGF2) , insulin-like growth factor-1 (IGF-1) and (IGF-2), fibroblast growth factor-2
(FGF-2), FGF-4 and epidermal growth factor (EGF) (35-37). Additional factors
examined include bone morphogenetic protein-2 (BMP-2), Interleukin-6 (IL-6) and
5

Activin-A. Results from these studies described relative improvement in survival plus
differentiation rate of transplanted cells, which remains insufficient to restore pre-MI
normalcy (1).
Involvement of TIMP-1 in cell proliferation has been demonstrated in various cell
types; however, whether TIMP-1 can promote stem cell differentiation is still unknown.
In our previously published work, we were able to enhance ES cell engraftment,
survival, and differentiation post transplantation in the MI heart by engineering them to
over-express TIMP-1 (20). Indeed, transplanted ES-TIMP-1 cells showed significantly
increased cardiac myocyte differentiation compared to non-engineered ES cells
demonstrating the role of TIMP-1 in stem cell differentiation. Based on this data, we
postulated that TIMP-1 released by ES-TIMP-1 cells may additionally activate
endogenous cardiac stem cells (CSCs) that express both CSC marker (c-kit) and TIMP1 receptor (CD63), leading to cardiac cell differentiation and myocardial regeneration
post MI injury.
CD63 marker is a cell surface receptor for TIMP-1 and a member of the
tetraspanin family (13; 15; 24). It is expressed in multiple cell types including cardiac
myocytes, endothelial cells and MSCs. However, no one has previously reported
existence of a CSC population which expresses CD63 marker. Furthermore, CD63
activation by TIMP-1 was shown to activate non-canonical β-catenin pathway leading to
enhanced cell proliferation in various cell types (25). However, whether activation of
CD63/β-catenin pathway in CD63+ve/c-kit+ve CSCs can trigger cardiac differentiation is
completely unknown.

6

Rationale and Aims
MI is a leading cause of death in the western world (54). The reported mortality
rate following MI is caused by the dramatic myocardium loss consecutive to ischemia
(5; 6; 30). Additionally, the pool of CSCs discovered in the heart are unable to
repopulate the infarcted myocardium with functional cardiac myocytes and vascular
cells to compensate for the millions of cells lost during an MI event (1; 5). To date, major
efforts have been made to salvage as much myocardium as possible in the first hours
following MI; however, the permanent damage caused by cell death eventually leads to
recurrent MIs and heart failure. Recently, regenerative medicine via cell transplantation
therapy has excited the scientific community as it offers the potential to repopulate the
infarcted area with functional cardiac myocytes (2). Somatic, iPS, adult and embryonic
stem cells have been utilized to replenish the myocardium with mitigated results (1). Our
engineered ES-TIMP-1 cells on the other hand demonstrated improved engraftment and
differentiation following transplantation when compared to regular ES cells (20). Based
on this data we postulated that TIMP-1 might be utilized to boost dormant endogenous
cardiac stem cells (CSCs) that express TIMP-1 receptor (CD63) leading to cardiac cell
differentiation and myocardial regeneration post MI injury.
The goal of the first study was to demonstrate existence of a CSC population
positive for c-kit (CSC marker) as well as CD63 (TIMP-1 receptor) from isolated murine
CSCs. We hypothesized that TIMP-1 released by ES-TIMP-1 cells activates isolated
CD63+ve/c-kit+ve CSCs, enhancing their proliferation, cardiac gene expression, and
differentiation into major cardiac cell types. To test our hypothesis, the following aims
were proposed:
1. Determine the existence of CD63+ve/c-kit+ve CSCs in isolated murine CSCs.
7

2. Assess the impact of ES-TIMP-1-CM and TIMP-1 on CD63+ve/c-kit+ve CSCs
proliferation and differentiation in vitro.
3. Identify the mechanism that mediates CD63+ve/c-kit+ve CSCs proliferation and
differentiation in vitro.
Within the second study, we aimed at identifying CD63+ve/c-kit+ve CSCs in vivo as
well as verifying the ability of TIMP-1 to activate these cells following MI. The goal of
this study was to validate whether intramyocardial delivery of ES-TIMP-1-CM or TIMP-1
would activate CD63+ve/c-kit+ve CSCs, enhance their proliferation and differentiation into
major cardiac cell types and replenish the lost myocardium. We hypothesized that
TIMP-1 transplantation into the infarcted myocardium targets CD63+ve/c-kit+ve CSCs,
binds to its receptor on their surface and activates β-catenin pathway, leading to
enhanced cell proliferation and differentiation. To test our hypothesis, we proposed the
following aims:
1. Determine the existence of CD63+ve/c-kit+ve CSCs in C57BL/6 and TIMP-1 KO
peri-infarcted hearts and verify the effect of intramyocardial delivery of TIMP-1 on
their proliferation.
2. Verify the effect of intramyocardial delivery of TIMP-1 on CD63+ve/c-kit+ve CSCs
differentiation following MI.
3. Identify mechanisms by which TIMP-1 mediates CD63+ve/c-kit+ve CSCs
proliferation and differentiation in vivo.
Finally, within the third study, we evaluated the impact of TIMP-1 transplantation
on adverse cardiac remodeling in the infarcted myocardium of C57BL/6 and TIMP-1 KO
mice. The goal of this study was to demonstrate that TIMP-1 is a multifunctional protein
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that not only enhances cardiac proliferation and differentiation but also prevents cardiac
cell death and fibrosis leading to overall better cardiac function. We hypothesized that
TIMP-1 would significantly inhibit cardiac apoptosis, fibrosis and improve cardiac
function 14 days post cardiac transplantation compared to ESCM treatment leading to
improved contractile function.

To test our hypothesis, we proposed to address the

following aims:
1. Evaluate the anti-apoptotic effect of TIMP-1 transplanted into the host
myocardium following MI.
2. Evaluate the anti-fibrotic effect of TIMP-1transplanted into the host myocardium
following MI.
3. Determine the impact of transplanted TIMP-1 infarct size and cardiac function
two weeks post-MI.
The long term goal of our research is to identify a multi-functional protein for
cardiac repair and regeneration following MI which targets endogenous CSCs, inducing
their proliferation and differentiation into all cardiac cell types, while effectively inhibiting
apoptosis and fibrosis.

Identification of such factor as well as its targeted CSC

population would provide a strong foundation for cardiac regeneration research.
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CHAPTER TWO: A CD63+ve/C-KIT+ve STEM CELL POPULATION ISOLATED FROM
THE MOUSE HEART
Abstract
Cardiac cell regeneration from endogenous cardiac stem cells (CSCs) following
MI is rather low. Therefore, identifying mechanisms to boost endogenous CSC
activation and participation in cardiac repair appears to be the most promising strategy
for MI patients. We previously engineered tissue inhibitor of metalloproteinases-1
(TIMP-1) overexpressing embryonic stem (ES-TIMP-1) cells and transplanted them into
the infarcted murine heart. Collected data demonstrated that TIMP-1 enhanced
transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post
transplantation. Therefore, we postulated that there may be a new stem cell population
present in the heart that is regulated by extracellular protein TIMP-1. Furthermore, we
hypothesized that this cell population has a potential for cell proliferation and
differentiation into cardiac cell types. Therefore, we isolated CSCs from four weeks old
C57BL/6 mice and cultured them in vitro in presence of ESCM, ES-TIMP-1-CM or
TIMP-1. Our immunostaining data demonstrated the existence of a novel CSC subpopulation, CD63+ve/c-kit+ve. When treated with TIMP-1, these cells showed significantly
(p<0.05) increased proliferation rates compared to control cells, enhanced TIMP-1
receptor (CD63), along with improved expression of phospho and total β-catenin
proteins as demonstrated by western blot analysis. Next, we demonstrate significantly
(p<0.05) improved cardiac myocyte, vascular smooth muscle cell, and endothelial cell
differentiation. Furthermore, our RT-PCR data shows increase in cardiac gene (GATA4, Mef2C, and Nkx-2.5) expression when compared to ESCM and control cells.
Collectively, this data, for the first time, establish the existence of a new CD63+ve/c-kit+ve
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CSC sub-population that has a significant potential for proliferation and differentiation
into cardiac cell types once stimulated with TIMP-1.
Keywords:
Cardiac Stem Cells, TIMP-1, c-kit, CD63, β-catenin, proliferation,
differentiation.
Introduction
The identification of cardiac stem cells (CSCs) in the adult heart greatly
challenged the belief that the heart is a terminally differentiated organ with no
regenerative capacity [1,2]. This information greatly increased enthusiasm among the
scientific community in their quest to repair damaged heart tissue following major
cardiac cell loss consequent to myocardial infarction (MI). CSCs

are localized

throughout the myocardium in clusters called niches [2]. They exhibit the capacity, both
in vivo and in vitro, to self-renew and differentiate into three major cardiac cell types
including cardiac myocytes, vascular smooth muscle (VSM) cells and endothelial cells
(ECs) [2-4]. Different sub-populations of CSCs have been identified based on
extracellular markers, such as side population (SP) cells, cardiac progenitor (CP) cells,
Sca-1+ve cells, cardiosphere cells, Isl1+ve cells and c-kit+ve cells [2]. CSCs are believed to
participate in cardiac cell turn over and homeostasis in the healthy and injured heart
[2,3]. However, the reported rate of myocyte regeneration from CSCs following MI is
rather low suggesting a limited regenerative potential of these resident stem cells [1,2].
Therefore, identifying mechanisms to boost endogenous CSC activation and their
participation in cardiac repair following MI appears to be the most promising strategy for
MI patients.
Multiple factors have been shown to promote stem cell recruitment, proliferation
and differentiation. Such factors include, but are not limited to, insulin growth factor
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(IGF), hepatic growth factor (HGF), granulocyte-colony stimulating factor (G-CSF),
vascular endothelial growth factor (VEGF), fibroblast growth factor-9 (FGF-9), and
transforming growth factor beta-2 (TGF-β2) [5]. Results from these studies described
relative improvement in cell proliferation and differentiation. However, their efficacy
remains insufficient to restore the post-MI myocardium to its non-pathological
architecture and functional capacity [6,7]. Therefore, we hypothesize that there may be
additional populations of CSCs present in the heart that could be activated by specific
factors, driving their proliferation and differentiation.
In

our

previously

published

work,

we

engineered

tissue

inhibitor

of

metalloproteinases-1 (TIMP-1) overexpressing ES cells and transplanted them into the
infarcted murine heart [8]. Collected data demonstrated that TIMP-1 enhanced
transplanted ES cell engraftment, survival and differentiation into cardiac myocytes post
transplantation [8]. In lieu of our previous findings, we postulated that TIMP-1 released
by ES-TIMP-1 cells may have additionally activated a subpopulation of endogenous
CSCs that express the CSC marker (c-kit) and TIMP-1 receptor (CD63).
To test the hypotheses, we aimed at identifying a subset of CSCs, CD63+ve/ckit+ve, from isolated murine CSCs. Next, we verified the effect of ES cell released
factors, present in their conditioned medium, with or without TIMP-1 (ESCM and ESTIMP-1-CM) or TIMP-1 alone on CD63+ve/c-kit+ve CSCs proliferation and differentiation
rates. Our data will show for the first time that we were able to identify a CD63+ve/c-kit+ve
sub-population of CSCs that is susceptible to proliferate, express cardiogenic factors,
and differentiate into major cardiac cell types upon treatment with either ES-TIMP-1-CM
or TIMP-1 in vitro.

17

Materials and Methods
Isolation of Cardiac Stem Cells (CSCs)
CSCs were isolated from 4 to 6 weeks old C57BL/6 mice hearts following
instructions provided with the Millipore CSCs Isolation kit (Cat# SCR061). In brief,
hearts were removed from the thoracic cavity, washed, and minced in CSC isolation
buffer. Next, a cell suspension was created through gentle agitation in dissociation
buffer for 1 hr and filtered using a self-contained Steriflip® filtration device. The filter
allows for the separation of larger cellular material while maintaining a sterile
environment. A differential gradient centrifugation was then applied to the cells, allowing
for the formation of a clear mid layer containing total CSCs. Isolated CSCs were plated
on gelatin-coated plates in CSCs maintenance medium (MM) purchased from Millipore
(Catalog# SMC101). During the first 7 to 12 days, cells gradually adhered to the plate
and were maintained regularly as per our standard protocol [8].

Preparation of ESCM, ES-TIMP-1-CM, and TIMP-1
ES-TIMP-1 cells were generated in our lab as previously described (8). Next,
condition medium (CM) was prepared by treating ES and ES-TIMP-1 cells with
Dulbecco’s Modified Eagle Medium (DMEM) containing leukemia inhibitory factor (LIF)
along with other components as we reported previously (5; 8). LIF was then removed
and cells were cultured for 48 hrs on gelatin-coated plates. Following incubation, ESCM
and ES-TIMP-1-CM were collected, filtered, and stored at -20oC. Recombinant mouse
TIMP-1 was purchased from R&D (cat # 980-MT) as a lyophilizat and reconstituted to a
concentration of 100µg/ml following manufacturer instructions and stored at -20oC.
18

CSCs treatment with ESCM, ES-TIMP-1-CM, and TIMP-1
CSCs were cultured in 6 well plates (80,000 cells/well) pre-coated with 0.1%
gelatin in MM until they adhered to the bottom of the plates. CSCs were then divided
into 4 groups (n=4 wells/group); Control (CSCs supplemented with 2ml growth media
(GM)), ESCM (CSCs supplemented with 2ml of ESCM), ES-TIMP-1-CM (CSCs
supplemented with 2ml of ES-TIMP-1-CM) and TIMP-1 (CSCs treated with 50ng TIMP1 in 2ml GM). Treated cells were incubated for 48 hrs followed by a media exchange
back to MM in all groups for an additional 24 hrs.

Plating and Immunostaining Detection of CD63+ve/c-kit+ve CSCs
CSCs were cultured in 8 well plates (15,000 cells/well) pre-coated with 0.1%
gelatin. Cells were divided, cultured, and treated as aforementioned. Next, cells were
washed and fixed with 10% formalin and Triton X for 10 min each followed by 1 hr with
10% normal goat serum (NGS; Vector Laboratories). To determine whether cells
express CD63 and c-kit markers, cells were incubated with anti-c-kit (1:50; Santa Cruz)
or anti-MLA-CD63 (1:500; Bios) rabbit monoclonal antibodies diluted in 10% NGS for 1
hr at room temperature or overnight at 4oC. Cell were then washed and incubated for 1
hr with secondary antibodies (goat anti-rabbit Alexa Fluor 568 (c-kit) or 660 (CD63)) at a
concentration of 1:20 diluted in 1x PBS. Total nuclei were detected by mounting each
section with Antifade Vectashield medium containing 4’,6-diamino-2-phenylindole
(DAPI; Vector Laboratories). Olympus and confocal ﬂuorescence microscopes were
used to visualize and quantify CD63+ve/c-kit+ve cells over total nuclei. Data are presented
as % of c-kit+ve cells over DAPI and % CD63+ve/c-kit+ve cells/total c-kit+ve cells.
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Immunostaining Determination of CD63+ve/c-kit+ve CSCs Differentiation into
Cardiac Myocytes, VSM Cells, and ECs
To verify whether treatment with ES-TIMP-1-CM or TIMP-1 can trigger CSC
differentiation into cardiac myocytes, VSMs, and/or ECs in vitro, CD63+ve/c-kit+ve cells
were stained with either sarcomeric (Src) α-actin, smooth muscle (SM) α-actin or CD31,
respectively [9]. After 1 hr incubation in NGS, cells were incubated with rabbit antiCD31 monoclonal antibody (1:25, Santa Cruz Biotechnologies) prepared in 10% NGS,
followed by FITC-conjugated goat anti-rabbit IgG secondary antibody (1:50, Invitrogen)
for 60 min. A mouse anti-mouse kit (MOM, Vector Laboratories) was used for SM and
Src-α-actin staining. After blocking, cells were incubated with anti-SM and anti-Src αactin antibodies (1:50 and 1:100 respectively, Sigma) for 30 min followed by an IgG
antibody and fluorescein avidin solution for 5 and 10 min each. Stained cells were then
mounted with Vectashield antifade medium containing DAPI (Vector Laboratories) for
nuclear visualization. Olympus, confocal microscope and Image J software were used
to quantify cardiac cell differentiation of CD63+ve/c-kit+ve cells using the following
formulas: % cardiac myocyte differentiation = Cells positive for Src α-actin, c-kit, and
CD63 over DAPI x 100. % VSM differentiation = Cells positive for SM α-actin, c-kit, and
CD63 cells over DAPI x 100. % ECs differentiation = Cells positive for CD31, c-kit, and
CD63 cells over DAPI x 100.

Cell Proliferation Assay
Previously treated cells were trypsinized and re-seeded on a 96 well plate at a
density of 104 cells/well supplemented with MM for 48 hrs. Next, cell proliferation was
measured using a tetrazolium salt cell proliferation assay kit (Cat# 10008883; Chayman
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Chemical). In brief, each well received 10µl of reconstituted tetrazolium salt solution and
the plate was incubated at 37oC on an orbital shaker for 3 hrs. Finally, absorbance of
each sample was read using a microplate reader at a 450nm. Measured absorbance
directly correlated with proliferation rate and was plotted as a bar graph.
Western Blot Detection of CD63, phospho (p) and total β-catenin Proteins
Expression
To determine CD63, phospho (p) and total β-catenin expression on isolated
CSCs as well as the effect of TIMP-1 on their expression, western blot analysis was
performed on cell lysates obtained from all four treatments groups as previously
described [10]. In brief, an equal amount of protein (100ug) was loaded on a 10%
polyacrylamide gel and subjected to electrophoresis at 150V for 1 hr. The gel was then
transferred for 45 min to a polyvinylidene fluoride membrane (BioRad) using a semi-dry
Immuno-Blot (Bio-Rad) at 15V. The membranes were blocked with 5% skim milk for 1
hr, incubated with primary rabbit antibodies (CD63/MLA1; cat # ABIN687742), (βcatenin (6B3) ; cat # 9582), phospho-β-catenin (Ser33/37/Thr41; cat # 9561, Cell
signaling), and β-actin (cat # 4967L from Cell Signaling) for one hr on an orbital shaker
at room temperature or at 4oC overnight, and incubated with anti-rabbit IgG horseradish
peroxidase secondary antibody (Cat # 7074S; Cell Signaling) for an additional 1 hr.
Blots were detected with Pierce® ECL Western Blotting Substrate (Thermo Scientific).

Real-Time PCR for GATA-4, Mef2C and Nkx-2.5
Cells were plated as previously described and total RNA was extracted using the
TRI® reagent protocol (Cat # T9424; Sigma Aldrich) (11). In brief, cells were lysed using
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1ml TRI reagent in an RNase free environment followed by a separation step in
chloroform and RNA precipitation in isopropyl alcohol. cDNA was synthesized from 1μg
total RNA using Superscript II reverse transcriptase and random primers (Bio-Rad).
Next, real-time quantitative PCR was performed using a CFX96™ Real-Time System
(Bio Rad). Supermix 2X (Life Technologies) containing FAM fluorescent dye and dNTPs
was added to the reaction mixture containing cDNA template and forward and reverse
primers. GATA-4, Mef2C, Nkx-2.5 and GAPDH primer assays were purchased from
Life Technologies. The following cycling conditions were used: 95˚C for 5 min followed
by 35 cycles of amplification (denature at 95˚C for 15 seconds and combined annealing
/extension at 60˚C for 60 seconds). The relative fold expression of GATA-4, Mef2C, and
Nkx-2.5 in each group was normalized against GAPDH and plotted.

Statistical Analysis
Data was analyzed using One-way analysis of variance (ANOVA) followed by the
Tukey Test. Data is presented as a mean ± SEM and statistical significance assigned
when p-value <0.05.

Results
Identification of CD63+ve/c-kit+ve Population from Isolated Murine CSCs.
CSCs were isolated from adult C57BL/6 mice hearts and cultured in vitro in the
presence of ESCM, ES-TIMP-1-CM or TIMP-1. Immunostaining to identify c-kit+ve and
CD63+ve/c-kit+ve CSCs was performed. Our data demonstrate that about 80% of isolated
CSCs were c-kit+ve (Figure1B) prior to treatment and up to 60% of these cells shared the
CD63 marker (Figure 1A and C). Following treatment, our data demonstrate the % of c22

kit+ve cells significantly increased in the ES-TIMP-1-CM group compared to the control
group (p<0.05, ES-TIMP-1-CM: 94%±1.91% vs. control: 76.5%±0.5%, Figure 1B).
However, the percent of double positive CD63+ve/c-kit+ve CSCs significantly increased
with both ES-TIMP-1-CM (95.5%±1.19%) and TIMP-1 (88.11%±4.3%) treatments
compared to ESCM (66.8%±1.06%) and control (60.61%±5.8%) cells (p<0.05, Figure
1C). Moreover, CD63, (p) and total β-catenin expression significantly increased upon
CSC treatment with TIMP-1 compared to control cells (p<0.05, Figures 1D-F). This data,
for the first time, identify a subset of CSCs that are CD63+ve/c-kit+ve and TIMP-1
enhances CD63 expression on their surface and β-catenin downstream of CD63 (Figure
1).

TIMP-1 Enhances CD63+ve/c-kit+ve CSC Proliferation in vitro
The effect of TIMP-1 on CD63+ve/c-kit+ve CSC proliferation was examined (Figure
2). Our data show enhanced cell proliferation in all treatment groups compared to
control cells (p<0.05, Figure 2A and B). Of note, although no significant difference
among treatment groups (ES-CM, ES-TIMP-1-CM, and TIMP-1) was achieved, it is
worth noting that TIMP-1 alone was able to induce a similar proliferation rate as that in
the ES-TIMP-1-CM group (Figure 2B). This data demonstrate that TIMP-1 alone can
promote CSC proliferation in vitro.

TIMP-1 Enhances Isolated CD63+ve/c-kit+ve CSC Differentiation into Cardiac
Myocytes, VSM Cells, and ECs
Triple immunostaining targeting newly differentiated CD63+ve/c-kit+ve CSCs
expressing either Src α-actin (cardiac myocytes), SM α-actin (VSM cells) or CD31 (ECs)
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was performed (Figure 3). Panels A, C, and E demonstrate confocal representative
images of CD63+ve/c-kit+ve CSCs undergoing cardiac myocyte, VSM cell, or EC
differentiation, respectively, with c-kit+ve cells shown in red (a,f and k), CD63+ve cells
shown in purple (b,g, and l), total nuclei shown in blue (c,h, and m), Src α-actin+ve, SM
α-actin+ve, or CD31+ve cells shown in green (d,i, and n, respectively), and merged
images of all four colors in e,j, and o. Our quantitative data revealed control and ESCM
groups underwent a similar rate of cardiac myocyte differentiation, while ES-TIMP-1-CM
and TIMP-1 treatments significantly enhanced this parameter relative to the control and
ESCM groups (p<0.05, ES-TIMP-1-CM; 31.24%±1.5% and TIMP-1; 29.39%±1.5% vs.
Control; 17.09%±0.6% and ESCM; 18.49%±0.9%, Figure 3B). A similar differentiation
pattern was also noted for VSM cells (p<0.05, ES-TIMP-1-CM; 27.94%±0.8% and
TIMP-1; 24.31%±1.6%) compared to control and ESCM groups (Control; 13.9%±0.35%
and

ESCM;

14.93%±1.11%,

Figure

3D)

and

ECs

(p<0.05,

ES-TIMP-1-CM;

14.7%±0.25% and TIMP-1; 15.9%±0.5%, Figure 3F) compared to control and ESCM
groups (Control; 9.01%±0.43% and ESCM; 10.53%±0.32%, Figure 3F). This overall
data demonstrate, for the first time, that TIMP-1 can trigger isolated CD63+ve/c-kit+ve
CSC differentiation into the three major cardiac cell types (cardiac myocytes, VSM cells,
and ECs).

TIMP-1 Enhances Expression of Cardiac Genes in Isolated CD63+ve/c-kit+ve CSCs
To verify expression of pro-cardiac markers GATA-4, Mef2C, and Nkx-2.5
following TIMP-1 treatment, RT-PCR analysis was performed (Figure 4). Our data
demonstrate no significant change in GATA-4 (Figure 4A), Mef2C (Figure 4B), and Nkx-
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2.5 (Figure 4C) mRNA levels in ESCM treated cells compared to control. However, cells
treated with ES-TIMP-1-CM and TIMP-1 showed significantly increased expression of
the three genes; GATA-4 (p<0.05, ES-TIMP-1CM; 6.81±1.02 and TIMP-1; 7.39±1.01 vs
Control; 1±0.71 and ESCM; 1.35±0.23, Figure 4A), Mef2C (p<0.05, ES-TIMP-1CM;
6.37±0.99 and TIMP-1; 7.34±0.33 vs Control; 1±0.8 and ESCM; 0.58±1.18, Figure 4B),
and Nkx-2.5 (p<0.05, ES-TIMP-1CM; 1.55±0.21 and TIMP-1; 1.4±0.03 vs Control; 1±0.1
and ESCM; 0.86±0.06, Figure 4C). This data further confirm that TIMP-1 enhances
CD63+ve/c-kit+ve CSC differentiation as demonstrated by increased cardiac gene
expression.

Discussion
Several CSC sub-populations have been described in the adult heart. However,
the role of each category in myocardial regeneration remains an open question [2,3].
Notably, endogenous cardiac progenitor cells were shown to give rise to differentiated
progeny including cardiac myocytes, VSM cells and ECs, in vitro as well as in vivo.
Nonetheless, the extent of cardiac regeneration observed in the post-MI heart by CSCs
remains insufficient to regain pre-infarct homeostasis [2,3,12]. Therefore, investigating
alternative ways to enhance the differentiation potential of endogenous CSCs remains
an important area of cardiac research. In the present study, we identify a novel subpopulation of CSCs, CD63+ve/c-kit+ve. When treated with TIMP-1, they showed 1)
increased proliferation rates compared to control cells, 2) enhanced CD63, (P) and
Total β-catenin expression, 3) significantly improved cardiac myocyte, VSM cell and EC
differentiation, and 4), increased cardiac gene (GATA-4, Mef2C and Nkx-2.5)
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expression. Taken together, this data, for the first time, establish the existence of a CSC
sub-population, which is CD63+ve/c-kit+ve and is specifically targeted by TIMP-1.
Furthermore, in the presence of TIMP-1, these cells undergo proliferation and
differentiation into major cardiac cells in vitro. We also postulate that TIMP-1 induced
CSC proliferation and differentiation is mediated through activation of CD63/β-catenin
pathway; however, additional experiments are required to confirm this hypothesis.
TIMP-1 is a glycoprotein that is ubiquitously expressed in numerous human cells
and tissues [8]. It is expressed in the normal heart to repress matrix metalloproteinases
(MMPs), which are responsible for extracellular matrix breakdown [8]. In the post-MI
heart, TIMP-1 has been extensively studied for its protective role against aberrant
collagen accumulation and fibrosis [8]. Furthermore, its involvement in cell proliferation
has been demonstrated in various cell types including human erythroid progenitor cells
and cancer cells [13,14]. However, whether TIMP-1 can promote stem cell
differentiation is still unknown.

In our previously published work, we were able to

enhance ES cell differentiation post-transplantation in the post-MI heart by engineering
them to over-express TIMP-1[8]. Therefore, we speculated that beyond its MMPdependent activity, TIMP-1 released by ES-TIMP-1 cells may additionally act as a
differentiation and proliferation factor on endogenous CSCs.
To test this hypothesis, we isolated murine CSCs and performed immunostaining
analysis to identify CD63+ve/c-kit+ve cells. Our data revealed the presence of a
CD63+ve/c-kit+ve sub-population, which makes up almost 60% of the whole c-kit+ve cell
population. Moreover, treatment with ES-TIMP-1-CM and TIMP-1 induced an increase
in CD63 expression on these cells as well as enhanced their proliferation rate to about
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80% of total c-kit+ve CSCs. CD63 is a transmembrane protein belonging to the
tetraspanin family and has been shown to be expressed in multiple cell types including
cardiac myocytes, ECs and human mesenchymal stem cells (hMSCs) [14,15]. However,
we are first to report its expression by CD63+ve/c-kit+ve CSCs. This data strongly support
our hypothesis and is in accordance with previously published work demonstrating
enhanced hMSCs proliferation through TIMP-1/CD63 interaction on the cell surface
[14].
Next, we aimed at investigating whether TIMP-1 alone could influence CD63+ve/ckit+ve CSC differentiation in vitro. Previously published studies demonstrated that ESCM
contains factors such as IGF1/2, bone morphogenetic protein-2 (BMP-2), plateletderived growth factor (PDGF) and VEGF that can promote cardiac differentiation [5].
However, none of these factors were able to promote significant cardiac differentiation
capable of restoring pre-MI capacity [16]. The role of TIMP-1 in cell differentiation, on
the other hand, has been the center of debate. In fact, TIMP-1 was reported to promote
oligodendrocyte differentiation and enhance central nervous system (CNS) myelination
as well as induce differentiation of germinal center B cells [17], while others claim it
inhibits hMSCs differentiation and promotes cell proliferation through modulation of
Wnt/β-catenin pathway [14]. Its implication in cardiac differentiation, however, has not
yet been delineated. In the present study, we provide evidence that TIMP-1 promotes
CD63+ve/c-kit+ve CSCs differentiation into the three major cardiac cells.
To further establish the involvement of TIMP-1 in CD63+ve/c-kit+ve CSC
differentiation, we measured cardiac gene expression on isolated CSCs. GATA-4,
Mef2C and Nkx-2.5 are cardiogenic factors first expressed during embryonic
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development to promote cardiac differentiation [18-21]. In the adult organ, these factors
are mainly expressed by adult stem cells undergoing cardiac differentiation. More
particularly, GATA-4 and Nkx-2.5 are linked to myocyte differentiation while Mef2C is
linked to both cardiac myocyte and vascular cell differentiation [20-21]. Based on these
previous findings, increased expression of these genes was assumed to be an indicator
of CSC differentiation. Interestingly, our data show ES-TIMP-1-CM and TIMP-1
significantly enhanced expression of all three cardiac genes while ESCM treatment did
not.
Taken together, our study demonstrates the existence of a CD63+ve/c-kit+ve CSC
population that is susceptible to proliferation and differentiation into cardiac myocytes
and vascular cells in vitro upon treatment with TIMP-1. Furthermore, we show that
cardiac differentiation is mediated through TIMP-1 binding to its receptor, CD63, leading
to activation of β-catenin protein that enhances cardiac gene expression (GATA-4,
Mef2C and Nkx-2.5). However, it is still unclear how β-catenin mediates cardiac
myocyte or vascular cell differentiation when receiving one unique signal, TIMP-1.
Furthermore, the ability of TIMP-1 to enhance CD63+ve/c-kit+ve CSC differentiation in vivo
has yet to be attempted. Therefore, future studies aiming at identifying CD63+ve/c-kit+ve
CSCs in vivo, their localization in respect to the infarct zone following MI, as well as
investigating their ability to migrate, proliferate and differentiate upon TIMP-1
transplantation is warranted.
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Figures

Figure 1. Identification of CD63+ve/c-kit+ve CSC Population from Isolated CSCs.
Panel A depicts representative confocal images of immunostained CD63 +ve/c+ve
kit CSCs with c-kit+ve cells shown in green (a), CD63+ve cells shown in red (b), DAPI
shown in blue (c) and merged images of all three channels (d). Boxed area with arrow
pointing towards it within d depicts an enlarged cell. Scale bar= 300µm. Graph 1B
demonstrates percent c-kit+ve CSCs/DAPI results. Figure 1C represents quantification
analysis of percent CD63+ve/c-kit+ve CSCs/ c-kit+ve cells. Figures 1D-F depict
densitometry analysis of CD63, β-catenin and (P)-β-catenin respectively over β-actin via
western blot. Data was collected from n=4-5 experiments per group.*p<0.05 vs. Control
and #p<0.05 vs. ESCM.
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Figure 2. TIMP-1 Enhances CD63+ve/c-kit+ve CSCs Proliferation. Bright field
representative images for all four control and treatment groups are depicted in Figure 2,
panel A (a, c, e, and g). Boxed areas from each photomicrograph are enlarged in A (b,
d, f, and h). Magnification = 10x. Quantitative data obtained from a proliferation assay
are depicted in Figure 2B. A.U= Arbitrary units. Data was collected from n=4-5
experiments per group. *p<0.05 vs. Control and #p<0.05 vs. ESCM.
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Figure 3. TIMP-1 Enhances CD63+ve/c-kit+ve CSCs Differentiation into Cardiac
Myocytes, VSMs, and ECs. Panels A, C, and E demonstrate confocal representative
images of CD63+ve/c-kit+ve CSCs undergoing cardiac myocyte, VSM cell, and ECs
differentiation, respectively, with c-kit+ve cells shown in red (a, f and k), CD63+ve cells
shown in purple (b, g, and l), total nuclei shown in blue (c, h, and m ), Src α-actin+ve, SM
α-actin+ve, and CD31+ve cells shown in green (d, i, and n), and a merged image of all four
colors in (e, j, and o). Each merged image contains an enlarged area boxed in the
corner. Scale bar = 300µm. Figure 3B represents quantitative analysis of percent
CD63+ve/c-kit+ve /Src-α-actin+ve CSCs over DAPI. Figure 3D represents quantitative
analysis of percent CD63+ve/c-kit+ve/SM-α-actin+ve CSCs over DAPI. Figure 3F
represents quantitative analysis of percent CD63+ve/c-kit+ve/CD31+ve cells over DAPI.
Data were collected from n=4-5 experiments per group. *p<0.05 vs. Control and
#p<0.05 vs. ESCM.
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Figure 4. TIMP-1 Enhances Expression of Cardiac Genes in Isolated CD63+ve/ckit+ve CSCs. Figure 4 depicts RT-PCR analysis of pro-cardiac markers GATA-4 (A),
Mef2C (B), and Nkx-2.5 (C). Data are plotted as mRNA relative fold change vs. control
group and normalized against GAPDH. Data were collected from n=4 experiments per
group.*p<0.05 vs. Control and #p<0.05 vs. ESCM.
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CHAPTER THREE: TIMP-1 ACTIVATED CD63+ve/C-KIT+ve CARDIAC STEM CELLS
DIFFERENTIATE INTO HEART CELL TYPES AND ENHANCE REGENERATION IN
THE INFARCTED MYOCARDIUM
Abstract
We previously demonstrated that embryonic stem (ES) cells over-expressing
tissue inhibitor of metalloproteinase-1 (TIMP-1) have increased potential to engraft and
differentiate into cardiac myocytes following transplantation in the infarcted heart.
However, the ability of TIMP-1 to activate endogenous cardiac stem cells (CSCs) and
enhance their differentiation potential is still unknown. Based on the observed beneficial
effects of TIMP-1 on transplanted ES cells, we postulated that TIMP-1 released by ESTIMP-1 cells may additionally activate endogenous cardiac stem cells (CSCs) that
express both CSC marker (c-kit) and TIMP-1 receptor (CD63) leading to cardiac
regeneration in the infarcted myocardium. Accordingly, C57BL/6 and TIMP-1 KO mice
underwent coronary artery ligation followed by intramyocardial delivery of 20µl of culture
media

(CC),

ES

conditioned

media

(ESCM),

ES-TIMP-1-CM

or

TIMP-1.

Immunohistochemistry analysis demonstrated a significant (p<0.05) increase in
CD63+ve/c-kit+ve CSCs following ES-TIMP-1-CM and TIMP-1 treatments compared with
controls. Interestingly, ratios of CD63+ve/c-kit+ve CSCs were significantly (p<0.05) lower
in TIMP-1 KO mice compared to C57BL/6 animals. RT-PCR analysis revealed TIMP-1
KO animals expressed significantly less CD63 and TIMP-1 mRNAs compared to
C57BL/6 mice. Additionally, activated CD63+ve/c-kit+ve CSCs were able to differentiate
into cardiomyocytes, endothelial and vascular smooth muscle cells. The differentiation
rate, however, was more robust in C57BL/6 mice compared to TIMP-1 KO mice. Finally,
we demonstrated that CSCs differentiation is regulated by CD63/β-catenin pathway.
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Overall, this study demonstrates that transplantation of TIMP-1 or ES-TIMP-1-CM into
the infarcted environment activates CD63+ve/c-kit+ve CSC population enhancing their
proliferation and cardiac regenerative potential through the CD63/β-catenin pathway.
Keywords:

Myocardial infarction, TIMP-1, Cardiac stem cells, CD63/β-catenin

pathway.

Introduction
The belief that the adult human heart is a post-mitotic organ incapable of
regenerating itself has long been challenged by multiple studies uncovering the
existence of small populations of stem cells residing within the myocardium, capable of
mitotic activity and differentiation into heart cells (1-3). Despite this, the reported rate of
myocyte regeneration is rather low; suggesting a limited regenerative potential of these
resident stem cell niches (1; 2; 10; 15; 16). Adult and embryonic stem cell based
transplantation therapies have gained much interest in the last decade for their ability to
regenerate injured myocardium (4; 7; 14-16; 18; 19; 23). Despite their varied
regenerative capabilities, the cell survival rate and differentiation were limited posttransplantation (1; 2; 15; 16). Nonetheless, the heart still benefits from factors released
from these cells. These factors were shown to play a role in cell self-renewal [(Insulin
Growth Factor (IGF), Hepatic Growth Factor (HGF) and Stem Cell Factor (SCF)],
neovascularization [Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth
Factor-9 (FGF-9)], and inhibition of adverse cardiac remodeling [Tissue Inhibitor of
Metalloproteinases-1 (TIMP-1)] (9; 11; 26-28).
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Our published data show that tissue inhibitor of metalloproteinases-1 (TIMP-1)
inhibits apoptosis and fibrosis in the infarcted heart (11). TIMP-1 Knocked out (KO) mice
showed exacerbated cardiac fibrosis two weeks after MI (12, 21). Furthermore, TIMP-1
KO mice treated with exogenous delivery of TIMP-1 or PD-166793, a pharmacological
inhibitor of MMPs, was sufficient to reduce cardiac fibrosis (12). Additionally, we
previously demonstrated that ES over-expressing TIMP-1 cells have increased potential
to engraft and differentiate into cardiac myocytes following transplantation in the
infarcted heart (11). However, the ability of TIMP-1 to activate endogenous CSCs and
enhance their differentiation potential is still unknown. Based on the observed beneficial
effects of TIMP-1 on transplanted ES cells, we postulate that TIMP-1 released by ESTIMP-1 cells may additionally activate endogenous cardiac stem cells (CSCs) leading to
cardiac regeneration (11).
TIMP-1 enhances proliferation of various cell types through regulation of the
CD63/β-catenin signaling pathway (13). CD63 is a cell surface receptor for TIMP-1 and
a member of the tetraspanin family. CD63 activation by TIMP-1 induces downstream
phosphorylation of β-catenin protein. The activated β-catenin then translocates to the
nucleus, interacts with T-cell factor-1 (TCF-1) transcription factor, and causes
transcription of target genes Cyclin D1, Survivin and Vascular Endothelial Growth
Factor (VEGF). If not activated, β-catenin is ubiquitinylated in the cytoplasm and
degraded through the activity of the Axin complex (5; 6).
In the previous chapter, we identified a novel cardiac stem cell population,
CD63+ve/c-kit+ve, from isolated murine CSCs. These cells were able to proliferate and
differentiate into cardiac myocytes, endothelial (ECs) and vascular smooth muscle
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(VSM) cells in vitro upon TIMP-1 treatment. However, identification of these cells in the
MI heart and their ability to promote sufficient cardiac regeneration upon TIMP-1
treatment is yet to be investigated.
The involvement of TIMP-1 and CD63/β-catenin pathway in cardiac regeneration
is not yet understood; therefore, we hypothesized that TIMP-1 enhances cardiac
regeneration in the MI heart through targeting a unique CD63+ve/c-kit+ve, CSC
population. These cells upon activation undergo cardiac differentiation resulting in
overall improved contractile function. Furthermore, we investigated CD63/β-catenin
pathway as the potential downstream mechanism controlling CSCs differentiation in the
infarcted heart.

Materials and Methods
Preparation of ESCM and ES-TIMP-1-CM
Embryonic stem (ES) cells overexpressing TIMP-1 factor were generated in our
lab as previously described (31). ES and ES-TIMP-1 cells were treated with Dulbecco’s
Modified Eagle Medium (DMEM) containing leukemia inhibitory factor (LIF) along with
other components as we reported. LIF was then removed and cells were cultured for 48
hours on gelatin coated plates. Following incubation, cell media enriched (Conditioned
media, CM) with factors released by both ES (ESCM) and ES-TIMP-1 (ES-TIMP-1-CM)
cells was collected, filtered, and stored in -20oC (27).

TIMP-1 Preparation
Recombinant mouse tissue inhibitor of metalloproteinases (TIMP-1) was
purchased from R&D (cat # 980-MT) as a lyophilizat and reconstituted to a
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concentration of 100ug/ml in a mixture of Tris (50mM), CaCl2 (10mM), NaCl (150mM),
and Brij35 (0.05%) dissolved in sterile double distilled water (ddH2O). Stock solutions
were aliquoted into 100µl volumes and stored in -20oC.

Myocardial Infarction and Treatment Administration
C57BL/6 (cat# 000664) and TIMP-1 KO on C57BL/6 background (B6.129S4Timp1tm1Pds/J; Cat# 006243) were purchased from Jackson Laboratories and bred at the
University of Central Florida (UCF) transgenic animal facility (TAF). All experiments
were in compliance with the UCF Institutional Animal Care and Use Committee (IACUC)
guidelines. 8 to 10 weeks old, mice were segregated into five study groups; Sham
(n=8), MI + Culture Media (CC; n=8), MI+ESCM (n=8), MI+ESTIMP-1-CM (n=8) and
MI+TIMP-1 (n=8). Myocardial infarction (MI) surgery was performed as previously
reported (9; 27; 29; 30). In brief, animals were sedated with 4% isoflurane and 2%
oxygen through an endotracheal intubation system (Minivent Type 845; Harvard
Apparatus). Animals were injected with an intramuscular dose of Buprenorphine
(0.5mg/kg) prior to surgery and 2-3 hours post-surgery to aid in pain relief. During the
procedure, the chest was shaved and a left thoracotomy was performed. The heart was
exposed and visualized under a light microscope to locate the Left Anterior Descending
(LAD) coronary artery coming down the left atrium and branching onto the left ventricle.
Using a surgical suture needle (Monofilament polypropylene non-absorbable suture,
7/0; cat # 8703P; CP Medical, Portland), a node was made around the LAD and the
artery was ligated. Artery ligation was confirmed by visualizing a bleaching area around
the ligation site, demonstrating a lack of blood supply to the ventricle. 20µl of CC,
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ESCM, ES-TIMP1-CM or TIMP-1 (200µg/kg of body weight) were injected at two sites
within the periphery of the bleached area (peri-infarct area) using a 700 Series
MICROTITER Syringe supplemented with a gauge floating needle (Hamilton CO.,
Nevada). Sham operated animals underwent complete surgery; however, the node
created around the LAD was left loose. The chest was closed and animals were allowed
to recover. Two weeks post-surgery, animals were sacrificed via isoflurane overexposure and cervical dislocation.

Preparation of Paraffin Sections
Mice hearts were harvested upon sacrifice and subjected to histological
evaluation as previously detailed (9; 27; 29; 30). The bottom portion containing both
ventricles was fixed in paraformaldehyde (PFA 4%) for 24 to 48 hours, dehydrated in
increasing concentrations of ethanol and embedded in paraffin. Resulting blocks were
subsequently sectioned using our microtome and 5um thickness sections were
generated and placed on microscope slides (Fisher Scientific). Prior to any staining,
sections were incubated for 30 minutes at 60oC to allow extra paraffin to melt. Complete
deparaffinization and rehydration was achieved by subsequent dipping in xylene two
times for 5 minutes, xylene: absolute alcohol (50:50), absolute alcohol (100%), and 90,
70, 50 and 30% ethyl alcohol solutions for 5 minutes each. Tissues were finally washed
in distilled water and phosphate-buffered saline (PBS 1X) for an additional 5 minutes.

Immunostaining Identification of CD63+ve/c-kit+ve CSCs in the Heart
To determine the existence of a subset CSC population expressing CD63 marker
in the murine heart, a double immunostaining for c-kit (CSCs marker) and CD63 (TIMP41

1 receptor) was performed on tissue sections from 7 to 8 animals per group from both
C57BL/6 and TIMP-1 KO mice. In brief, sections were incubated with 10% normal goat
serum (NGS; Vector Laboratories) for 1 hour to ensure blockage of nonspecific sites
followed by one hour at room temperature or overnight at 4 oC incubation with anti-c-kit
(1:50; Santa Cruz), or anti-MLA-CD63 (1:500; Bios) rabbit monoclonal antibodies diluted
in 10% NGS. Sections were then washed and incubated for 1 hour with secondary
antibody goat anti-rabbit Alexa Fluor 568 for c-kit and 660 for CD63 at a concentration
of 1:20 diluted in 1x PBS. Total nuclei were detected by mounting each section with
Antifade Vectashield medium containing 4’,6-diamino-2-phenylindole (DAPI; Vector
Laboratories). Olympus and confocal ﬂuorescence microscopes were used to visualize
and quantify CD63+ve/c-kit+ve cells over total nuclei. Four representative areas per
section were taken and quantified using Image J software. Data is presented as % of
CD63+ve/c-kit+ve cells/total DAPI.

Immunostaining Determination of CD63+ve/c-kit+ve CSCs Differentiation.
To verify whether ES-TIMP-1CM and TIMP-1 treatments can trigger CSC
differentiation into cardiac myocytes (CM), vascular smooth muscle (VSM) and
endothelial cells (ECs) in the MI heart, previously double stained CD63+ve/c-kit+ve cells
were triple stained with either sarcomeric (Src) α-actin, smooth muscle (SM) α-actin, or
CD31, respectively (11; 29; 30).

After 1 hour incubation in NGS, sections were

incubated with 1:25 dilution of rabbit anti-CD31 monoclonal antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA) prepared in 10% NGS, followed by FITC-conjugated
goat anti-rabbit IgG secondary antibodies (Invitrogen) diluted at 1:50 in PBS for 60
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minutes. For both Src and SM α-actin staining, mouse anti-mouse kit (MOM, Vector
Laboratories) was used. In brief, sections were incubated for 1 hour in MOM blocking
reagent followed by 5 minutes in protein working solution (PWS) provided in the kit.
Next, anti-SM and anti-Src α-actin antibodies (1:50 and 1:100 respectively, Sigma) were
diluted in PWS and exposed on the top of the sections for 30 min followed by IgG
antibody and fluorescein avidin solution for 5 and 10 min each.
Finally, triple stained sections were mounted with Vectashield antifade medium
containing DAPI (Vector Laboratories) for nuclear visualization. Four representative
images per slide were taken using Olympus and confocal microscopes and Image J
software was used to quantify cardiac cell differentiation using these formulas: % CM
differentiation = triple Src α-actin+ve/c-kit+ve/CD63+ve cells over total Src α-actin cells x
100. % VSM differentiation = triple SM α-actin+ve/c-kit+ve/CD63+ve cells over total
vascular nuclei x 100. % ECs differentiation = triple CD31 +ve/c-kit+ve/CD63+ve cells over
total vascular nuclei x 100. Of note, representative pictures in Figure 6 were taken from
the peri-infarct zone of the heart where we localized CSCs differentiating into cardiac
myocytes.

Real-Time PCR for CD63 and TIMP-1 mRNAs
Total RNA was extracted using TRI® reagent protocol (Cat # T9424; Sigma
Aldrich). In brief, heart pieces from different study groups were homogenized using 1ml
TRI reagent in an RNase free environment followed by a separation step in chloroform
and RNA precipitation in isopropyl alcohol. RNA purity and concentration was verified
using spectrophotometer analysis from absorbance readings of 260 and 280nm. An
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absorbance ratio of A260/A280 ranging between 1.8 to 2.0 was considered pure. cDNA
was synthesized from 1 μg total RNA using Superscript II reverse transcriptase and
random primers (Bio-Rad). Next, Real-time quantitative PCR was performed using a
CFX96™ Real-Time System (Bio Rad). Supermix 2X; Life Technologies containing
FAM fluorescent dye and dNTPs in a reaction buffer was added to the reaction mixture
containing cDNA template, forward, and reverse primers. CD63, TIMP-1 and GAPDH
primer assays were purchased from Life Technologies. The following cycling conditions
were used: 95˚C for 5 min followed by 35 amplification cycles at 95˚C to denature for 15
seconds and 60˚C for combined annealing/extension for 60 seconds. The relative fold
expression of CD63 and TIMP-1 in each group was normalized against GAPDH and
plotted.

Western Blots for CD63, β-catenin and phospho-β-catenin Proteins
To determine the effect of TIMP-1 on CD63/β-catenin pathway, protein level was
measured on heart homogenates taken from all treatment groups and both mouse
strains using SDS-PAGE. In brief, an equal amount of protein (100ug) was loaded on a
10% polyacrylamide gel and subjected to electrophoresis at 150V for 1 hour. The gel
was then transferred for 45 min to a polyvinylidene fluoride membrane (PVDF; BioRad)
presoaked in methanol and transfer buffer using a semi-dry Immuno-Blot (Bio-Rad) at
15V current. The membranes were then blocked with 5% skim milk for 1 hour and
incubated with primary rabbit antibodies (CD63/MLA1; cat # ABIN687742, Antibodies),
(β-catenin (6B3) ; cat # 9582, and phospho-β-catenin (Ser33/37/Thr41; cat # 9561, Cell
signaling) and (β-actin; cat # 4967L from Cell Signaling) for one hour on an orbital
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shaker at room temperature or at 4oC overnight. Membranes were then incubated with
anti-rabbit IgG horseradish peroxidase secondary antibody (Cat # 7074S; Cell
Signaling) for one hour, and blots were detected with Pierce® ECL Western Blotting
Substrate (Thermo Scientific) (22).

Statistical Analysis
All data presented in this study were subjected to statistical analysis using
SigmaStat 3.5 software. One-way analysis of variance (ANOVA) was run for all
experiments followed by Tukey test and statistical results were presented as a mean ±
standard error of the mean (SEM). The difference between two study groups was
considered statistically significant if the P<0.05.

Results
ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs
Proliferation in the Infarcted Myocardium
The effect of transplanted ES-TIMP-1-CM and TIMP-1 on proliferation of
endogenous CD63+ve/c-kit+ve CSCs was examined in the infarcted TIMP-1 KO and
C57BL/6 hearts. Our c-kit cell specific staining combined with CD63 confirms that
following intramyocardial delivery of ES-TIMP-1-CM and TIMP-1, percent of CD63+ve/ckit+ve CSCs significantly increases (p<0.05, ES-TIMP-1-CM: 2.05%±0.33% and TIMP-1:
1.46%±0.14%) compared with (Sham: 0.48%±0.11% and MI+CC: 1.14%±0.12%) in
C57BL/6 mice. TIMP-1 KO mice showed similar pattern but with lower ratios (p<0.05,
ES-TIMP-1-CM 1.52%±0.24% and TIMP-1: 0.86%±0.1%) compared with (Sham:
0.29%±0.08% and MI+CC: 0.53%±0.05%) (Figure 5).
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ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs
Differentiation into CMs, VSMs, and ECs in the Infarcted Myocardium
The effect of transplanted ES-TIMP-1-CM and TIMP-1 on endogenous
CD63+ve/c-kit+ve CSCs differentiation into CM, VSM, and ECs was examined in the
infarcted TIMP-1 KO and C57BL/6 hearts. Triple immunostaining targeting newly
differentiated CMs from CSCs expressing c-kit, CD63 and Src α-actin was performed.
Our quantitative data revealed no significant alteration in cardiac myocyte differentiation
in MI and MI+ESCM treatment compared to control in both TIMP-1 KO and C57BL/6
mice, while enhanced cardiac myocyte differentiation was observed following ES-TIMP1-CM

and

TIMP-1

treatments

relative

to

controls

(p<0.05,

ES-TIMP-1-CM;

24.72%±1.32% and TIMP-1; 22.91%±1.03%) against (Sham; 6.93%±0.59%, MI+CC;
8.91%±0.75%, and ESCM; 10.18%±0.82%) in C57BL/6 and (p<0.05, ES-TIMP-1-CM;
14.72%±0.71% and TIMP-1; 11.35%±0.86%) against (Sham; 4.35%±0.64%, MI+CC;
4.36%±0.35%, and ESCM; 6.48%±1.65%) in TIMP-1 KO mice (Figure 6).
One of the major cardiac cell types lost during a myocardial event are VSM cells,
which make up cardiac vasculature (29). We aimed at investigating the ability of ESTIMP-1-CM or TIMP-1 to promote their regeneration from CD63+ve/c-kit+ve CSCs using a
triple immunostaining targeting newly differentiating CSCs that express three markers;
c-kit, CD63 and SM-α-actin (Figure 7). C57BL/6 data revealed decreased sm-α-actin
cells in MI+CC group compared to control animals, although not significant (MI+CC;
5.81%±1.59% vs Sham; 8.78%±1.77%). Conversely, TIMP-1 KO animals showed a
slight increase in VSMs differentiation in MI+CC and ESCM against sham animals, with
no significance (MI+CC; 3.14%±0.46%, and ESCM; 3.36%±0.21% against Sham;
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1.69%±0.22%). ES-TIMP-1-CM and TIMP-1 treatments both significantly (P<0.05)
increased smooth muscle differentiation compared to MI+CC and Sham groups in both
strains (p<0.05, ES-TIMP-1-CM; 23.47%±5.30% and TIMP-1; 19.13%±2.66%) in
C57BL/6 and (p<0.05, ES-TIMP-1-CM; 7.17%±1.34% and TIMP-1; 5.43%±0.28%) in
TIMP-1 KO mice against controls (Figure 7C).
Endothelial cells are important components of cardiac vasculature (29). Thus, we
aimed at analyzing their regeneration rate from CD63+ve/c-kit+ve CSCs in the same
aforementioned conditions. A triple immunostaining targeting newly differentiating CSCs
expressing c-kit, CD63 and CD31 was performed. C57BL/6 data revealed significant
depletion of CD63+ve/c-kit+ve CSCs positive for CD31 marker in MI+CC compared to
Sham (P<0.05, MI+CC; 4.99%±0.3% vs Sham; 6.91%±0.64%). This decrease was
significantly (p<0.05) reverted by ESCM, ES-TIMP-1-CM and TIMP-1 treatments
(P<0.05,

ESCM;

7.86%±0.1%,

ES-TIMP-1-CM;

11.32%0.42%

and

TIMP-1;

10.20%±0.47%). Of note, ES-TIMP-1-CM treatment showed the strongest effect on
endothelial cell differentiation when compared to sham, MI+CC and ESCM groups.
TIMP-1 KO data demonstrated no significant change in MI+CC and ESCM groups
compared to Sham; however, ES-TIMP-1-CM and TIMP-1 significantly increased ratios
of CD63+ve/c-kit+ve CSCs differentiating into ECs compared to MI+CC and Sham groups
(P<0.05, ES-TIMP-1-CM; 10.78%±0.92% and TIMP-1; 9.03%±0.51% vs MI+CC;
5.65%±0.43% and Sham; 5.55%±0.39%) (Figure 8C). Taken all together, differentiation
data demonstrate ratios of CD63+ve/c-kit+ve cells positive for CM, VSM, and ECs markers
are significantly elevated following ES-TIMP-1-CM and TIMP-1 treatments in both
C57BL/6 and TIMP-1 KO mice compared to their controls, suggesting TIMP-1 may have
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activated endogenous CD63+ve/c-kit+ve CSCs and enhanced their differentiation into
CMs, VSMs and ECs in both C57BL/6 and TIMP-1 KO mice (Figure 6-8).
Representative confocal images demonstrating c-kit/CD63+ CSCs differentiation
into CMs, VSMs, and ECs are shown in Figure 6, 7 and 8 respectively. In each figure,
panel A represents C57BL/6 representative figures and panel B depicts TIMP-1 KO
representative images. Each panel demonstrates CD63 +ve cells in purple (a,f,k,p and
u), c-kit

+ve

in red (b,g,l,q and v), Src-α-actin, SM or CD31+ve in green (c,h,m,r and w),

total nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Enlarged images
of triple stained cells are depicted at the margin of merged images (Figures 6-8).

Effect of ES-TIMP-1-CM and TIMP-1 on Endogenous TIMP-1 and CD63 mRNAs
Expression
To determine effect of ES-TIMP-1-CM and TIMP-1 delivery on endogenous
TIMP-1 and CD63 expression, we performed RT-PCR analysis for both mRNAs on
heart tissue specimens collected from TIMP-1 KO and C57BL/6 animals. RT-PCR data
shows near null expression of TIMP-1 mRNA in TIMP-1 KO mice compared to wild type
(Figure 9A). In parallel, levels of CD63 mRNA significantly dropped in the TIMP-1
deficient mice compared to C57BL/6 (p<0.05, TIMP-1 KO; 0.05±0.01 vs C57BL/6;
1±0.0), suggesting a strong correlation between TIMP-1 and CD63 expression in the
heart (Figure 9B). Next, we compared expression levels of TIMP-1 and CD63 following
MI and exogenous delivery of ESCM, TIMP-1 and ES-TIMP-1-CM treatments.

Our

data show no effect of any treatments on TIMP-1 mRNA levels in TIMP-1 KO animals.
However, C57BL/6 mice showed a noticeable decrease in TIMP-1 expression in MI+CC
group followed by 2 to 4 fold increase upon ES-TIMP-1-CM and TIMP-1 treatments,
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respectively (Figure 9C). Next, CD63 mRNA data demonstrate a slight decrease in
CD63 mRNA expression following MI+CC and ESCM treatment; however, no
significance was achieved relative to sham group. ES-TIMP-1-CM and TIMP-1 treated
C57BL/6 mice induced 4 and 2.5 fold increase in CD63 expression compared to MI+CC
and sham C57BL/6 animals. Ratios of CD63 in TIMP-1 KO animals followed the same
trend described in C57BL/6 mice; however, at much lower ratios (TIMP-1 KO; ES-TIMP1-CM; 0.07±0.03 and TIMP-1; 0.07±0.04) vs (C57BL/6 ES-TIMP-1-CM; 3.98±0.92 and
TIMP-1; 2.21±0.6) (Figure 9D).

Mechanism of TIMP-1 Mediated CD63+ve/c-kit+ve CSCs Regeneration in the
Infarcted Myocardium
We compared the effect of TIMP-1 delivery on CD63, phospho (P), and total βcatenin proteins on heart homogenates (Figure 10). Western blot results on TIMP-1 KO
mice showed significantly (p<0.05) decreased CD63 levels in MI+CC and MI-ESCM
groups compared to control. This decrease was drastically (p<0.05) reversed in ESTIMP-1-CM and TIMP-1 treatments (Figure 10D). C57BL/6 mice showed a slight
decrease in CD63 levels in MI+CC group against control; however, no significance was
achieved. Additionally, ESCM and TIMP-1 treatments slightly increased CD63
expression without reaching significance. Nonetheless, ES-TIMP-1-CM treatment
showed a strong increase (p<0.05) in CD63 levels (Figure 10A). Next, we measured
total β-catenin protein levels (Figure 10B and E). TIMP-1 KO data showed a significant
decrease in β-catenin protein in MI+CC and ESCM groups relative to sham, however,
upon ES-TIMP-1-CM and TIMP-1 treatments, the decrease in β-catenin significantly
improved compared to MI+CC and MI+ESCM animals (Figure 10E). C57BL/6 western
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blot analysis revealed no significant change in all study groups except ES-TIMP-1-CM
which showed significantly (p<0.05) increased β-catenin protein expression as
compared to sham and MI+CC animals (Figure 10B). Finally, we evaluated the ability of
exogenous TIMP-1 to activate β-catenin. Densitometry analysis of (P)-β-catenin levels
in TIMP-1 KO mice demonstrated a drastic decrease (p<0.05) in (P)-β-catenin levels in
MI+CC and ESCM groups compared to sham; however, ES-TIMP-1-CM and TIMP-1
treatments largely increased (p<0.05) (P)-β-catenin levels (Figure 10F). C57BL/6 hearts
showed no significant variation in (P)-β-catenin levels in Sham, MI+CC and MI+ESCM
animals; however, upon ES-TIMP-1-CM and TIMP-1 treatments, activated (P)-β-catenin
levels strongly (p<0.05) increased (Figure 10C). Overall, this data suggest ES-TIMP-1CM and TIMP-1 delivery activated CD63/β-catenin pathway following MI.

Discussion
Stem cell transplantation has largely been utilized as a source for cardiac
regeneration following MI. These cells include ES, Bone Marrow (BM) derived stem
cells, hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and umbilicalcord-blood-derived mesenchymal stem cells (UCB-MSCs) (1; 2). The results from these
experiments were mitigated by inconsistent cell survival following transplantation and a
limited trans-differentiation rate given their non-cardiogenic origin (1; 2; 14-16; 18; 19;
25). CSCs are thus, prime candidates for cardiac transplantation given their cardiac
differentiation potential. Published work demonstrated intramyocardial delivery of
cardiac progenitor cells (CPCs) to the injured rat myocardium differentiate into cardiac
myocytes and vascular cells (24). Activation of endogenous CSCs was additionally
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suggested to occur through paracrine factors released by transplanted CPCs; however,
the nature of these factors was yet to be determined.
We previously investigated the ability of ES over-expressing TIMP-1 cells to
regenerate the lost myocardium in the murine model for MI (11). Data collected from
this study demonstrated enhanced cardiac regeneration regardless of the low
engraftment rate of transplanted cells. We therefore hypothesized that TIMP-1 released
by transplanted ES cells might target a subset of endogenous CSCs which express
TIMP-1 receptor (CD63) and trigger their differentiation into the three main cardiac
populations; cardiac myocytes, smooth muscle, and endothelial cells.
To address this hypothesis, we performed MI surgery on TIMP-1 KO and
C57BL/6 mice followed by intramyocardial delivery of ESCM, ES-TIMP-1-CM or
recombinant TIMP-1 protein. ESCM, TIMP-1, and ES-TIMP-1-CM groups were
performed to compare the effect of factors released by stem cells, TIMP-1, or both
respectively. We stipulated that TIMP-1 alone would be sufficient to activate CD63+ve/ckit+ve CSCs and regenerate the damaged myocardium. Our data indeed demonstrated
that ESCM performed less than TIMP-1 and ES-TIMP-1-CM did not provide a better
outcome when compared to TIMP-1 alone, demonstrating that other factors do not play
a role in CD63+ve/c-kit+ve activation. Our collected data demonstrate in vivo delivery of
ES-TIMP-1-CM or TIMP-1 equivalently: 1) enhance CD63+ve/c-kit+ve CSCs proliferation
and differentiation into cardiac myocytes, endothelial and vascular smooth muscle cells,
2) promote additional CD63 expression in the heart, 3) up regulate phospho and total βcatenin expression. This study additionally demonstrates that TIMP-1 deletion
significantly reduces the number of CD63+ve/c-kit+ve CSCs population in the heart and
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exogenous delivery of TIMP-1 is sufficient to replenish their pool. We believe that
endogenous TIMP-1 triggers expression of CD63 receptor on c-kit positive cells as
demonstrated by the dramatic decrease in CD63 mRNA expression in TIMP-1 KO
hearts. Furthermore, our data shows TIMP-1 enhances CD63+ve/c-kit+ve CSCs
proliferation which explains the decreased number of CD63+ve/c-kit+ve cells in the heart
of TIMP-1 KO vs. C57 control animals. This finding is in accordance with prior study
suggesting paracrine factors released by transplanted CPCs activate endogenous
CPCs (64), and previously published data suggesting TIMP-1 released by stem cells
mediates human mesenchymal stem cell (hMSC) proliferation and differentiation (13).
Next, we provide evidence that CD63+ve/c-kit+ve CSC activation is mediated
through CD63/β-catenin pathway as suggested by increased CD63, β-catenin and
phospho-β-catenin expression in MI hearts treated with ES-TIMP-1-CM and TIMP-1.
Enhancement of β-catenin and phospho-β-catenin expression in C57BL/6 infarcted
heart mice after ES-TIMP-1-CM and TIMP-1 treatment and/or their rescuing after these
same interventions in TIMP-1 KO mice might be explained by activation of CD63 which
induces dephosphorylation of Axin complex preventing β-catenin ubiquitination and
degradation.

Additionally,

released

β-catenin

phosphorylation prior to nucleus translocation.

is

subsequently

activated

by

We additionally stipulate that

endogenous TIMP-1 triggers expression of additional CD63 receptor on c-kit positive
cells by activating CD63/β-catenin pathway in a positive feedback loop. Furthermore,
our data show TIMP-1 enhances CD63+ve/c-kit+ve CSCs proliferation which additionally
explains the increased amount of available CD63 mRNA as well as the dramatic
decrease in CD63 mRNA expression in TIMP-1 KO hearts.
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Activated

CD63/β-catenin

pathway

and

subsequent

enhanced

cardiac

differentiation following TIMP-1 administration contradicts published work attesting
TIMP-1 enhances cell proliferation but hinders cardiac differentiation in hMSCs through
blockage of the CD63/β-catenin pathway (8). Nonetheless, our results are in
accordance with multiple other studies demonstrating ability of ES cells to differentiate
into cardiac cells through activation of β-catenin pathway and subsequent expression of
cardiac genes, such as Nkx2.5, β-myosin heavy chain (β-MHC) and cardiac troponin T
(cTnT) (17; 20).
In the present study, we choose to identify c-kit+ve CSCs because they represent
the most prevalent and extensively characterized subset of CSCs pool. Other CSCs
involve side population (SP) cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardio
sphere cells and Isl1+ve cells, which are less abundant and poorly characterized (2). It is
therefore, imperative to identify the relative contribution of CD63+ve CSCs that are not ckit+ve. CD63 was also shown to be expressed in adult cardiac myocytes and vascular
endothelial cells (13). These cells might have differentiated from CD63+ve/c-kit+ve CSC
origin and kept CD63 marker expression when fully differentiated. Furthermore, we and
others have previously demonstrated that TIMP-1 reduces cardiac apoptosis, fibrosis
and enhances cell proliferation following MI; however, not much is known about the
molecular mechanism mediating this protective effect and whether ES-TIMP-1-CM or
ESCM would provide a better protection (11). In the current paper we stipulate that the
anti-apoptotic, anti-fibrotic and proliferative role of TIMP-1 in the heart is most likely
mediated through CD63 receptor maintained on these cells. Additional protective
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mechanisms mediated by other factors present in the conditioned media are also very
likely. Nonetheless, future studies are warranted to support or refute this hypothesis.
In conclusion, our data demonstrate for the first time existence of a unique
subset of CSCs in the peri-infarct area, double positive for c-kit and CD63 markers.
These cells can be triggered to differentiate into cardiac cells by exogenous delivery of
TIMP-1 factor or ES-TIMP-1-CM.

Stimulation of CD63+ve/c-kit+ve CSCs leads to

enhanced cardiac regeneration. Additionally, we provide evidence that CD63+ve/c-kit+ve
CSCs

activation

is

mediated

through

CD63/β-catenin

pathway.

This

paper

demonstrates for the first time that besides the anti- cardiac remodeling effect of TIMP1, this molecule has a strong regenerative potential. This multifaceted characteristic of
TIMP-1 makes it a suitable candidate for MI patients.
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Figures

Figure 5. ES-TIMP-1-CM and TIMP-1 Enhance Endogenous CD63+ve/c-kit+ve CSCs
Proliferation in the Infarcted Myocardium. A triple immunostaining targeting
CD63+ve/c-kit+ve CSCs niche and sarcomeric (Src) α-actin (cardiac myocytes marker)
was performed and representative confocal images are shown in Figure 5A. CD63+ve
cells are shown in purple (a,f,and k), c-kit +ve in red (b,g and l), Src-α-actin+ve in green
(d,i and n), total nuclei in blue (c, h and m), and merged images (e,j and o). Scale bar =
50µm (a-e) and 25µm (f-j). Enlarged images of double stained cells are depicted in (ko). Ratio of double positive CD63+ve/c-kit+ve cells over total DAPI was quantified on
C57BL/6 and TIMP-1 KO mice and results are plotted in Figure 5B. Data was collected
from n=5 animals per group and 1 section per animal.*p<0.05. vs Sham, #p<0.05 vs
MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group means the given
significance above it applies to both strains.
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Figure 6. ES-TIMP-1-CM and TIMP-1 Enhance Cardiac Myocyte Differentiation of
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium. A triple immunostaining
targeting newly differentiated CSCs expressing the three markers; c-kit, CD63 and
sarcomeric (Src) α-actin (cardiac myocytes marker) was performed and representative
confocal images are shown in Figure 6A for C57BL/6 and Figure 6B for TIMP-1 KO.
CD63+ve cells are shown in purple (a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), Src-αactin +ve in green (c,h,m,r and w), total nuclei in blue (d,i,n,s and x), and merged
images (e,j,o,t, and y). Scale bar = 25µm. Enlarged images of triple stained cells are
depicted at the margin of merged images. Figure 6C shows % CD63+ve/c-kit+ve CSCs
positive for sarcomeric α-actin. Data was collected from n=5 animals per group and 1
section per animal.*p<0.05. vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM.
Brackets over each group means the given significance above it applies to both strains.
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Figure 7. ES-TIMP-1-CM and TIMP-1 Enhance Smooth Muscle Differentiation of
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium. A triple immunostaining
targeting newly differentiated CSCs expressing the three markers, c-kit, CD63 and
smooth muscle (SM) α-actin was performed. Representative confocal images are
shown in Figure 7A for C57BL/6 and Figure 7B for TIMP-1 KO. CD63+ve cells are shown
in purple (a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), Sm-α-actin +ve in green (c,h,m,r
and w), total nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Scale bar
= 25µm. Enlarged images of triple stained cells are depicted at the margin of merged
images. Histogram 7C shows quantitative data of % CD63+ve/c-kit+ve also positive for
smooth muscle cell marker. Data was collected from n=5 animals per group and 1 to 2
section per animal. *p<0.05. vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM.
Brackets over each group means the given significance above it applies to both strains.
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Figure 8. ES-TIMP-1-CM and TIMP-1 Enhance Endothelial Cell Differentiation of
CD63+ve/c-kit+ve CSCs in the Infarcted Myocardium. Figure 8 depicts confocal
representative images taken from a triple immunostaining targeting newly differentiated
CSCs expressing the three markers: c-kit, CD63 and CD31. Figure 8A represents
C57BL/6 experiment and Figure 8B for TIMP-1 KO. CD63+ve cells are shown in purple
(a,f,k,p and u), c-kit +ve in red (b,g,l,q and v), CD31+ve in green (c,h,m,r and w), total
nuclei in blue (d,i,n,s and x), and merged images (e,j,o,t, and y). Scale bar =25µm.
Enlarged images of triple stained cells are depicted at the margin of merged images.
Histogram 8C shows quantitative data of % CD63+ve/c-kit+ve CSCs also positive for
endothelial cell marker. Data was collected from n=5 animal per group and 1 to 2
section per animal. *p<0.05. Vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM.
Brackets over each group means the given significance above it applies to both strains.
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Figure 9. Effect of ES-TIMP-1-CM and TIMP-1 on Endogenous TIMP-1 and CD63
mRNAs Expression in the Infarcted Myocardium. CD63 and TIMP-1 mRNA levels
were measured on heart tissue specimens collected from C57BL/6 and TIMP-1 KO
control animals. Quantitative RT-PCR relative fold change data for TIMP-1 mRNA is
plotted in Figure 9A and CD63 mRNA in Figure 9B. Histograms 9C and 9D demonstrate
levels of these two molecules in MI+CC and MI plus exogenous delivery of ESCM,
TIMP-1 and ES-TIMP-1-CM treatments in both animal models. Data was collected from
n=5 samples per group for TIMP-1 and n=6 to 7 for CD63 measurements.*p<0.05. vs
Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group
means the given significance above it applies to both strains.
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Figure 10. Mechanism of TIMP-1 Mediated CD63+ve/c-kit+ve CSCs Regeneration in
the Infarcted Myocardium. Figure 10 depicts densitometry analysis of western blots
for CD63, activated phospho (p) and total β-catenin proteins measured on heart
homogenates from both C57BL/6 mice (Figures 10A-C) and TIMP-1 KO mice (Figure
10D-F). Representative blots for each histogram are also included above each
corresponding histogram. Data was collected from n=4-6 samples per group. *p<0.05 vs
Sham, #p<0.05 vs MI+CC and $ p<0.05 vs MI+ESCM. Brackets over each group
means the given significance above it applies to both strains.
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CHAPTER FOUR: TIMP-1 AND ES CELLS OVEREXPRESSING TIMP-1 CONDITION
MEDIA BLUNT ADVERSE CARDIAC REMODELING FOLLOWING MYOCARDIAL
INFARCTION
Abstract
Transplanted

mouse

ES

cells

overexpressing

tissue

inhibitor

of

metalloproteinase-1 (TIMP-1) in the infarcted myocardium demonstrated inhibited
adverse cardiac remodeling and improved cardiac function. However, whether these
beneficial effects are provided by transplanted cells or TIMP-1 factor released in the
conditioned media (CM) was previously unknown. Therefore, we hypothesized that
intramyocardial delivery of ES-TIMP-1-conditioned medium (CM) or TIMP-1, following
myocardial infarction (MI), inhibit cardiac apoptosis and fibrosis and resume contractile
function. Accordingly, age matched C57BL/6 and TIMP-1 KO mice were subjected to
coronary artery ligation followed by intramyocardial delivery of 20µl of culture media
(CC), ESCM, ES-TIMP-1-CM or TIMP-1. TUNEL staining, Caspase-3 activity ELISA,
Masson’s Trichrome, and echocardiography analysis were used to assess apoptosis,
fibrosis, and heart function respectively. Two weeks post-MI, ES-TIMP-1-CM and TIMP1 significantly (p<0.05) reduced overall cardiac apoptosis as well as Caspase-3
mediated cardiac myocytes cell death compared with ESCM group in both TIMP-1 KO
and control animals. Infarct size, interstitial and vascular fibrosis were significantly
(p<0.05) decreased in the ES-TIMP-1-CM and TIMP-1 groups compared to controls.
Furthermore, we demonstrated that TIMP-1 factor alone is sufficient to significantly
resorb cardiac remodeling in both TIMP-1 KO and control animals regardless of the
severity of damage. Finally, echocardiography data showed fractional shortening and
ejection fraction were significantly (p<0.05) improved in the ES-TIMP-1-CM and TIMP-1
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groups in both strains. Our data suggest that ES-TIMP-1-CM or TIMP-1 alone provide
an equivalent protection against adverse cardiac remodeling and shall be considered as
potential therapeutic tools for MI patients.
Keywords: Myocardial Infarction, TIMP-1, Apoptosis, Fibrosis, Cardiac Function.

Introduction
Adverse cardiac remodeling is the process by which the myocardium size,
conduction and function are altered as a result of myocardial infarction (MI),
myocarditis, or idiopathic dilated cardiomyopathy (1). The gross pathological changes
involved in cardiac remodeling are; massive cardiac myocyte cell loss through
apoptosis, increased infiltration of collagen fibers throughout the infarct zone and
cardiac myocyte hypertrophy, leading to deregulated contractile function (1-3). Cardiac
myocyte apoptosis following MI activates cardiac fibroblasts, which are the main cellular
modulators of cardiac fibrosis. They control extracellular matrix (ECM) turn over through
secretion of matrix metalloproteinases (MMPs), otherwise called Matrixins, and their
direct inhibitors; tissue inhibitor of metalloproteinases (TIMPs) (3-6). The main function
of matrixins is the degradation and removal of ECM molecules as well as stimulation of
collagen I, III and IV production from fibroblasts (7; 8). Following MI, upregulation of
MMP2 and MMP9 has been correlated with aberrant collagen build up in the infarct area
(7; 8). Concurrently, levels of TIMP-1 have been shown to be significantly downregulated

post

MI

(4).

Furthermore,

published

data

demonstrated

TIMP-1

downregulation correlates with exacerbated cardiac myocyte apoptosis and increased
fibrotic tissue (7).

Increased cardiac myocyte death and accumulated collagen
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deposition within the infarct zone leads to ventricular wall stiffening resulting in impaired
systolic and diastolic functions (1; 4; 7).
Up regulation of TIMP-1 in the MI heart by direct delivery of TIMP-1 protein or
vector to the peri-infarct area has demonstrated decreased overall infarct size, infiltrated
fibrosis and cardiac myocyte apoptosis which positively impacted contractile function
(9). Similarly, pharmacological inhibition of MMPs using PD-166793 compound was
able to rescue the MI heart (7). Others have investigated stem cell transplantation as a
way to replace apoptotic cardiac myocytes and vasculature in different animal models
for MI (4; 8; 10; 11). Stem cells have the potential to regenerate the myocardium and
consequently prevent fibrotic tissue accumulation. However, their survival rate in the
host myocardium is very timid which greatly limits their differentiation potential in vivo
(12; 13). Previously, we have generated embryonic stem (ES) cells overexpressing
TIMP-1 factor (ES-TIMP-1 cells). When transplanted to the MI heart, these cells
demonstrated limited engraftment to the host myocardium; however, collected data
showed a significant decrease in cardiac remodeling parameters as well as improved
functional capacity of the heart (4). Therefore we hypothesized that TIMP-1 released by
ES-TIMP-1 cells provided the aforementioned protective effect to the heart.
Furthermore, ES cells are known to secrete other beneficial factors such as; Insulin
Growth Factor (IGF), Hepatic Growth Factor (HGF), Stem Cell Factor (SCF), and
Vascular Endothelial Growth Factor (VEGF), all of which regulate cell proliferation and
angiogenesis and might be aiding TIMP-1 in blunting left ventricular remodeling (14-16).
In the present study, we compared the anti-cardiac remodeling effect of direct
transplantation of TIMP-1 protein, ES condition media (CM), which contains factors
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released by ES cells, and ES-TIMP-1-CM in the MI heart of both C57BL/6 and TIMP-1
KO mice. Our study will provide evidence that ES cells released factors combined with
TIMP-1 or TIMP-1 alone provide an equivalent protection against adverse cardiac
remodeling and shall be considered as potential therapeutic tools for MI patients.

Materials and Methods
Condition Media Preparation from ES and ES-TIMP-1 Cells
Embryonic Stem (CGR8) cells overexpressing TIMP-1 factor (ES-TIMP-1 cells)
were generated by transfection of pTurboFP635-C (Homemade) vector encoding red
fluorescent protein (RFP), mouse TIMP-1 cDNAs and neomycin resistance gene.
Transfection was carried out using Lipofectamine 2000 (Invitrogen). Resulting cells
were selected by treatment with G418 antibiotic (Invitrogen) (4). Condition media
preparation from both cell lines was carried out as previously detailed (4). Briefly, ES
and ES-TIMP1 cells were cultured till confluence in presence of DMEM containing LIF,
sodium pyruvate, glutamine, β-mercaptoethanol, penicillin-streptomycin, nonessential
amino acids, and 15% ES cell-qualified fetal bovine serum (Invitrogen). LIF was then
removed and cells were cultured for 48 hours on gelatin coated plates supplemented
with cell culture media (CC). Following the 48 hours incubation, cell media containing
factors released from ES and ES-TIMP-1 cells were collected in separate tubes, labeled
ESCM and ES-TIMP-1-CM respectively and saved for future use in -20oC.

TIMP-1 Preparation
Recombinant mouse TIMP-1 (R&D; cat # 980-MT) lyophilizat was reconstituted
in sterile water containing a mixture of Tris (50mM), Cacl2 (10mM), NaCl (150mM), and
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Brij35 (0.05%) to a concentration of 100ug/ml. aliquots of 100µl volumes were made and
stored in -20oC.

Myocardial Infarction and Treatment Administration
All animal procedure detailed hereafter was approved by the University of Central
Florida (UCF) Institutional Animal Care and Use Committee (IACUC). C57BL/6 and
TIMP-1 KO on C57BL/6 background (B6.129S4-Timp1tm1Pds/J; Jackson laboratories;
Cat# 006243) were bred at the UCF’s Transgenic Animal Facility (TAF) until 8 to 10
weeks old. Next, equal number of males and females from both strains were separated
into five study groups; Sham (n=8), MI+Culture Media (CC; n=8), MI+ESCM (n=8),
MI+ES-TIMP-1-CM (n=8) and MI+TIMP-1 (n=8), where “n” is the number of animals per
study group. Left anterior descending (LAD) coronary artery ligation surgery was
performed on the last four groups following previously reported procedure (17-19). In
brief, animals were sedated with 4% isoflurane and 2% oxygen provided through an
endotracheal

intubation

system

(Minivent

Type

845;

Harvard

Apparatus).

Buprenorphine intra-muscular injection (0.5mg/kg) was also given to animals prior to
surgery and 2-3 hours post-surgery to aid in pain relief. As part of the pre-operative
procedure, the chest was shaved, alcohol sterilized and covered with betadine. A
thoracotomy was then performed, the heart was exposed and the LAD ligated using a
surgical suture needle (Monofilament polypropylene non-absorbable suture, 7/0; cat #
8703P; CP Medical, Portland). Artery ligation was confirmed when a bleaching area
around the ligation site occurs following ligation. 20µl of CC, ESCM, ES-TIMP1-CM or
TIMP-1 (200ug/kg of body weight) was injected at two peri-infarct sites using a 700
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Series MICROTITER Syringe supplemented with a gauge floating needle (Hamilton CO,
Nevada). Sham operated animals were put under the same stress but the ligation was
kept loose. Following treatments, thoracotomy was sutured back up and the mice were
allowed to recover under strict supervision. Two weeks post-surgery, mice were
sedated with Isoflurane overdose and sacrificed by cervical dislocation.

Tissue Embedding and Preparation of Paraffin Sections
Mice hearts were excised two weeks following surgery, washed in 1 X PBS and
the bottom portion containing both ventricles was fixed in paraformaldehyde (PFA 4%)
(17-19). PFA stored hearts were dehydrated by exposure to serial concentrations of
Ethanol and embedded in paraffin. 5µm thickness sections were made using a tissue
processor than placed on microscope slides (Fisher scientific). The wax remaining on
the tissue section was melted down by incubating section in 60 oC for 30 minutes. Prior
to any staining, deparaffinization and rehydratation of the tissue specimens was
achieved by sequential dipping in xylene and descending concentrations of alcohol.
Tissues were finally washed in distilled water and phosphate-buffered saline (PBS 1x)
for an additional 5 minutes.

Determination of Infarct size
A standard Masson's trichrome protocol was performed on tissue sections to
detect collagen deposition in the MI area (4). In brief, deparaffinized and rehydrated
sections were successively immersed into Weigert iron hematoxylin, acid fuchsin,
phosphomolybdic-phosphotungstic acid, and aniline blue. Under bright filed Olympus
microscope, healthy cells stained in pink, nuclei stained in dark purple and collagen
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deposits stained in bright blue. Whole heart micrographs were taken under 2 X objective
and Image J software was used to measure the whole heart and the infarct site area.
Infract size was calculated using this formula: LV infarct area/LV area x 100%.

Determination of Infiltrated Interstitial and Vascular Fibrosis
Interstitial fibrosis defined as the amount of collagen infiltrated within the
interstitial space was detected on previously Masson’s Trichrome stained sections. In
brief, four to six photomicrographs were taken under 20X bright field light Olympus
microscope objective and the blue area (collagen) was measured in each photo using
Image J software. The average of 4 measured areas was taken as representative of the
section. Seven to eight hearts per group were used for statistical analysis (4). Vascular
fibrosis was averaged from 6 different vessels per sections using this equation: vascular
fibrosis/ vessel area x 100% in one to two sections from seven to eight hearts per
group.

Determination of Apoptotic Nuclei and Apoptotic Cardiac Myocytes by TUNEL
Staining
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining
was performed on tissue sections to determine the ratio of apoptotic cells versus total
viable cells between the different study groups. Briefly, deparaffinized and rehydrated
heart sections were permeabilized with proteinase K (25 ug/ml in 100mM Tris-HCL),
then immunostained using TUNEL kit (TMR red; Roche Applied Bio Sciences) which
stains apoptotic nuclei in red. For detection of apoptotic cardiac myocytes, previously
TUNEL stained section were double stained with mouse anti sarcomeric α-actin (Sigma
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Aldrich) following mouse on mouse protocol (MOM, Vector Laboratories). Succinctly,
sections were incubated for 1 hour in MOM blocking reagent followed by 5 mins in
protein working solution (PWS) provided with the kit. Next, sections were incubated for
30 min with anti sarcomeric α-actin antibody (1:100), followed by 5 mins of IgG antibody
and 10 mins of Fluorecin avidin solution. Finally, to detect whether cardiac myocytes
apoptosis was mediated by Caspase-3 cascade, a third staining was performed using
anti-rabbit polyclonal Caspase-3 primary antibody (1:1000, cell signaling). Hearts were
incubated overnight with primary antibody followed by anti-rabbit secondary Alexa 660
(1:50, Invitrogen) for an hour. To detect total nuclei, sections were covered with antifade
vectashield mounting medium containing 4’,6-diamino-2-phenylindole (DAPI; Vector
Laboratories). Olympus fluorescence microscope and LEICA laser scanning confocal
microscope were used to identify triple stained sections and 4 images of randomly
selected areas per sections were taken under 20X objective. Data per animal was
obtained by averaging measurements from all four areas. Percent TUNEL positive
nuclei was measured using the following formula: total positive cells/Total DAPI X100%.
For Apoptotic cardiac myocytes: double positive cells for Sarcomeric α-actin and
TUNEL were quantified and divided by total cardiac myocytes number. 1 to 2 sections
per heart were analyzed and 5 to 6 hearts per group were used for statistical analysis
(4).

Caspase-3 Activity Assay
To verify cardiac apoptosis is mediated by Caspase-3 machinery, heart
homogenates from all study groups and both strains were assayed with the Caspase-3/
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CPP32 colorimetric assay kit (K106-200, Biovision). Briefly, 1:10 dilutions were made
from homogenates using lysis buffer provided with the kit and protein estimation was
measured using Bio-Rad protein assay kit. Caspase-3 assay steps were carried out on
a 96 well plate according to manufacturer’s protocol until detection of blue color
indicative of presence of active form of the protein. A microtiter plate reader was used to
measure intensity of the blue color under 400nm to 405nm. Caspase-3 activity graph
was plotted as arbitrary units (A.U) (4).

Echocardiography Analysis for Cardiac Function
To evaluate how ES-TIMP-1-CM and TIMP-1 treatments translate at the
physiological level, echocardiography analysis was performed on mice hearts at day 14
post surgery using a Phillips Sonos 5500 Ultrasound system in a similar fashion
previously reported (17-19). Mice were sedated with 2 to 4% volume of isoflurane and
2% oxygen delivered via nose cone, their chest hair was removed and the sonogram
probe was positioned on top of the chest facing the head to record two dimensional (2D)
images in a long axis projection with a guided M-mode. Three to four 2D images where
obtained and the left ventricular fractional shortening (%FS) and left ventricular ejection
fraction (%EF) were recorded. %EF was calculated using this formula [(left ventricular
volume at end diastole (EDV) - left ventricular volume at end systole (ESV)/ left
ventricular volume at end diastole (EDV)]. EDV and ESV were calculated using
Teichholz formula:
EDV= [7/ (2.4+LVIDd)].LVIDd3.
ESV= [7/ (2.4+LVIDs)].LVIDs3.
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Left ventricular interior diameter during diastole (LVIDd) and left ventricular
interior diameter during systole (LVIDs) were manually measured on the motion mode
screen shots taken for each animal.

Statistical Analysis
Data are reported as Means ± SEMs (Standard Error of Mean). Significance was
determined using one-way analysis of variance (ANOVA) performed on SigmaStat3.5
software followed by Tukey or Bonferroni tests. Difference between two study groups
was considered statistically significant if p<0.05.

Results
ES-TIMP-1-CM and TIMP-1 Blunt Apoptosis in the Infarcted Myocardium
To demonstrate the anti-apoptotic effect of ES-TIMP-1-CM and TIMP-1 on the
host myocardium following MI, tissue sections were subjected to TUNEL staining which
distinguishes apoptotic nuclei with a red color. Quantification of percent apoptotic nuclei
against total DAPI revealed apoptosis dramatically increases in MI-CC hearts relative to
control (p<0.05, MI-CC;2.1%±0.3% vs Sham; 0.3%±0.05%) for C57BL/6 and (p<0.05,
MI-CC; 2.86%±0.4% vs Sham; 0.4%±0.07%) for TIMP-1 KO mice (Figure 11B).
Importantly, ESCM, ES-TIMP-1-CM and TIMP-1 transplantation significantly mitigated
apoptosis (p<0.05, ESCM; 0.95%±0.12%, ES-TIMP-1-CM; 0.31%±0.07% and TIMP-1;
0.71%±0.1%) in C57BL/6 mice and (p<0.05, ESCM; 1.59%±0.2%, ES-TIMP-1-CM;
0.45%±0.17% and TIMP-1; 0.67%±0.1%) in TIMP-1 KO mice relative to their respective
MI-CC groups (Figure 11B). Notably, although all treatments significantly decreased
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(p<0.05) apoptosis compared to MI-CC, only ES-TIMP-1-CM and TIMP-1 groups were
able to decrease it up to Sham levels (Figure 11B).
Next, we aimed at evaluating whether ES-TIMP-1-CM and TIMP-1 treatments
were able to blunt Caspase-3 mediated cardiac myocytes apoptosis. Therefore, a triple
immunostaining for TUNEL, sarcomeric α-actin and Caspase-3 markers was performed
on heart sections. Figure 12A depicts confocal representative images obtained from MICC animals from C57BL/6 mice (a-f) and TIMP-1 KO (g-l) demonstrating apoptotic
nuclei in red (a and g), Caspase-3 positive cells in yellow (b and h), sarcomeric α-actin
positive cells in green (c and i), and total nuclei in blue (d and j). A merge of four
stainings is depicted in white (e and k) and enlarged areas from e and k are presented
in (f) and (l), respectively.

Our quantitative data for percent TUNEL positive cardiac

myocytes show cardiac myocyte apoptosis significantly elevated following MI (p<0.05,
MI-CC;2.45%±0.29% vs Sham; 0.36%±0.06%) for C57BL/6 and (p<0.05, MI-CC;
5.42%±0.68% vs Sham; 0.42%±0.03%) for TIMP-1 KO mice (Figure 12B). However,
upon treatment with ESCM, ES-TIMP-1-CM or TIMP-1, these ratios significantly
reduced compared with MI-CC hearts and this regardless of the strain (p<0.05, ESCM;
1.07%±0.11%, ES-TIMP-1-CM; 0.84%±0.06% and TIMP-1; 0.92%±0.19%) in C57BL/6
mice and (p<0.05, ESCM; 2.9%±0.3%, ES-TIMP-1-CM; 1.01%±0.14% and TIMP-1;
1.22%±0.17%) in TIMP-1 KO mice (Figure 12B). Data additionally show ES-TIMP-1CM and TIMP-1 provide the greatest improvement against non-treated MI hearts in
TIMP-1 KO mice when compared to ESCM treatment, while the three aforementioned
treatments had similar effects on cardiac myocyte apoptosis in C57BL/6 mice (Figure
12B). Interestingly, caspase-3 activity measured on heart homogenates collected from
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all study groups and both stains revealed similar pattern to cardiac myocyte apoptosis
(Figure 12C). In brief, data show increased caspase-3 activity in MI-CC animals for both
strains; however, ES-TIMP-CM and TIMP-1 treatments significantly (p<0.05) reduced its
activity. Of note, even though ESCM treatment decreases Caspase-3 activity, it did not
reach significance against MI-CC animals for either strain (Figure 12C).

Reduced Interstitial and Vascular Fibrosis Following ES-TIMP-1-CM and TIMP-1
Transplantation in the Infarcted Myocardium
Masson’s trichrome stained heart sections were used to quantify interstitial and
vascular fibrosis. Figure 13A depicts interstitial fibrosis (IF) representative images
obtained from all study groups per strain.

Measured interstitial fibrosis area

demonstrate a significant (p<0.05) increase in IF area (mm2) following MI in both
C57BL/6 and TIMP-1 KO animals compared to their respective controls (p<0.05, MI-CC;
1.04±0.1 vs Sham; 0.03±0.008) for C57BL/6 and (p<0.05, MI-CC; 1.43±0.2 vs Sham;
0.03±0.01) for TIMP-1 KO mice (Figure 3B). Our data additionally demonstrate
significantly (p<0.05) decreased interstitial fibrosis following ESCM, ES-TIMP-1-CM and
TIMP-1 treatments compared to MI-CC hearts. Notably, ES-TIMP-1-CM and TIMP-1
showed the greatest decrease in IF measurements regardless of the strain when
compared to ESCM treatment (p<0.05) (Figure 13B). Next, we quantified accumulated
vascular fibrosis (VF) and our data revealed significantly increased (p<0.05) collagen
deposition around vessels in MI-CC animals (Figure 14B). This increase was however,
significantly blunted with ESCM, ES-TIMP-1CM and TIMP-1 treatments (p<0.05 vs MICC) in both C57BL/6 and TIMP-1 KO animals (Figure 14B). Moreover, ES-TIMP-1-CM
and TIMP-1 treatments were able to blunt VF and IF in a similar fashion for both strains
77

even though TIMP-1 KO animals demonstrated higher IF and VF measurements
following MI compared to their C57BL/6 counterparts.

Reduced Infarct Size Following ES-TIMP-1-CM and TIMP-1 Transplantation in the
Infarcted Myocardium
To evaluate the effect of ES-TIMP-1-CM and TIMP-1 treatments on the infarct
area post MI, heart sections were subjected to Masson’s trichrome staining and whole
heart images were taken under 2x objective of bright field Olympus microscope.
Representative whole-heart images depicting infarct size from both strains and all
corresponding treatment groups are represented in Figure 15A. Quantification analysis
revealed that the dramatic infarct size induced by MI surgery was significantly blunted
following transplantation of ESCM, ES-TIMP-1-CM and TIMP-1 (p<0.05, ESCM;
8.24%±0.92%, ES-TIMP-1-CM; 3.21%±0.6% and TIMP-1; 4.85%±1%) in C57BL/6 mice
and (p<0.05, ESCM; 9.5%±1.58%, ES-TIMP-1-CM; 4.79%±0.8% and TIMP-1;
4.25%±0.51%) in TIMP-1 KO mice relative to their respective MI-CC groups (C57BL/6,
MI-CC; 14.25%±1.25% and TIMP-1 KO, MI-CC; 17.69%±0.5%) (Figure 15B). ESCM
treatment alone provided a significant (p<0.05) improvement in infarct size reduction,
however, to a lower degree compared to the later treatments. More importantly, TIMP-1
KO animals showed a drastic increase in infarct size compared to their C57BL/6
counterparts, however, ES-TIMP-1-CM and TIMP-1 treatments were able to significantly
(p<0.05) resorb the infarct area in a similar fashion for both strains (Figure 15).
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Improved Heart Function Following ES-TIMP-1-CM and TIMP-1 Treatments in the
Infarcted Myocardium
Cardiac function was measured 14 days after MI procedure. Our data suggest a
significant improvement in cardiac fractional shortening (FS) following ES-TIMP-1-CM
and TIMP-1 treatments in C57BL/6 mice (p < 0.05, ES-TIMP-1-CM; 40.89% ± 1.33%
and TIMP-1; 37.64% ± 0.92% vs MI+CC; 32.35% ± 0.34% and ESCM; 34.55% ±
1.46%) and TIMP-1 KO mice (p < 0.05, ES-TIMP-1-CM; 38.21% ± 1.67% and TIMP-1;
36.68% ± 1.13% vs MI+CC; 27.85% ± 1.28% and ESCM; 31.57% ± 1.95%) (Figure
16B). However, improved function following either ES-TIMP-1-CM or TIMP-1
transplantation was lower than sham in both TIMP-1 KO (46.89% ± 1.37%) and
C57BL/6 (51.83% ± 1.34%) groups. We also determined that left ventricular ejection
fraction (EF) was more significantly impacted in C57BL/6 than TIMP-1 KO hearts
following MI. However, its levels significantly (p<0.05) increased in the ES-TIMP-1-CM
(72.59% ± 3.29%) and TIMP-1(69.54% ± 0.52%) compared with MI+CC (59.68% ±
0.4%) and ESCM (63.45% ± 3.77%) in TIMP-1 KO mice (Figure 16C). Moreover,
significantly (P<0.05) increased ejection fraction was also observed in the ES-TIMP-1CM (83.58% ± 1.34%) and TIMP-1 (69.04% ± 0.56%) groups compared with MI+CC
(62.30% ± 0.52%) and ESCM (64.1% ± 2.1%) groups in C57BL/6 mice (Figure 16B).
Finally, improved EF ratios following ES-TIMP-1-CM transplantation were significantly
(p<0.05) lower than sham in both TIMP-1 KO (81.37% ± 1.31%) and C57BL/6 (83.58%
± 1.34%). TIMP-1 treatment data for the same parameter showed significance (p<0.05)
only in C57BL/6 animals against sham, whereas TIMP-1 KO animals resumed normal
ejection fraction.
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Discussion
In the current study, we have examined the protective potential of ES-TIMP-1CM and TIMP-1 against adverse cardiac remodeling consecutive to MI in TIMP-1 KO
mice and their controls (C57BL/6 mice). Our cumulative data demonstrate ES-TIMP-1CM and TIMP-1 significantly: 1) blunt percent cardiac apoptosis, 2) decrease Caspase3 mediated cardiac myocyte cell death, 3) reduce interstitial and vascular fibrosis, 4)
shrink infarct area and most importantly, 5) improve left ventricular contractile function in
both C57BL/6 and TIMP-1 KO animals. Finally, we show evidence that TIMP-1 is
sufficient to attenuate adverse remodeling to a similar extent between TIMP-1 KO mice
and C57BL/6 mice.
Cardiac apoptosis is considered the hallmark of cardiac ischemia. It is mediated
by two distinct pathways; the extrinsic and the intrinsic pathways (20; 21). Extrinsic
pathway is triggered by extracellular death ligands such as FAS, tumor necrosis factor
(TNF)-α, or TRAIL, while intrinsic pathway is mediated through activation of Caspases
activity (20; 21). TIMP-1 factor has been shown to blunt apoptosis in different cancer
cell lines through modulation of the intrinsic pathway, however, not much is known
about its anti-apoptotic role in the heart (9; 22). We have previously demonstrated that
TIMP-1 released by ES cells inhibits apoptosis on cultured H9C2 cells (embryonic
cardiac

myoblasts)

previously

exposed

to

hydrogen

peroxide

(H2O2)

(23).

Furthermore, our next published data demonstrated ES-TIMP-1 cell delivery in the MI
heart decreased Caspase-3 mediated apoptosis, however, whether this effect is
mediated through TIMP-1 or other factors additionally released by ES-TIMP-1 cells was
not clear (4). In the present study, we provide evidence that TIMP-1 alone is sufficient to
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decrease overall cardiac apoptosis and specifically blunt Caspase-3 activity in cardiac
myocytes following MI (Figures 11 and 12). Furthermore, TIMP-1 KO animals showed
significantly higher Caspase-3 activity in cardiac myocytes compared to control mice
following MI (Figure 12C). This further demonstrates the anti-apoptotic role of TIMP-1 in
cardiac myocytes through inhibition of Caspase-3 activity.
Cardiac myocyte apoptosis in the infarct and peri-infarct area precipitates
collagen deposition in the interstitial and vascular spaces leading to stiffening of the left
ventricle (9; 17; 22). TIMP-1 ability to blunt cardiac fibrosis through inhibition of MMPs is
a well-documented fact (9; 17; 22). Additionally, previously published work has shown
decreased fibrosis following ES-TIMP-1 cells transplantation in the MI heart (4). This
decrease was associated with inhibition of endogenous MMP-9, a known promoter of
collagen secretion and ECM degradation in the heart (4). However, it was unclear
whether ES-TIMP-1-CM could provide a better outcome than TIMP-1 alone. Therefore,
we measured interstitial and vascular fibrosis on TIMP-1 KO and C57BL/6 infarcted
hearts following ESCM, ES-TIMP-1-CM and TIMP-1 treatments. Our data showed that
although all treatments were efficient at blunting fibrosis (interstitial and vascular); the
last two treatments provided the best outcome regardless of the strain. ES cells have
been shown to release other anti-fibrotic factors such as hepatic growth factor (HGF)
which has been linked to decreased fibrosis in lung alveolar epithelium (24). This
explains, in part, the anti-fibrotic effect of our transplanted ESCM. However, TIMP-1
seems to provide a stronger anti-fibrotic effect as demonstrated by the extent of fibrosis
decrease we report following TIMP-1 treatment compared with any other combined
factors released by ES cells.
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Finally, we aimed at determining whether combined inhibition of apoptosis and
fibrosis in the host myocardium contribute to decreased infarct size and improved
cardiac function. Infarct size measurements are based on measurement of the infarcted
area in tissue sections of the heart (25). Our data is in corroboration with previously
published work, which demonstrated larger infarct area in TIMP-1 KO animals
compared with their C57BL/6 counterparts two weeks following MI (7; 17; 22).
Additionally, ESCM, ES-TIMP-1-CM and TIMP-1 treatments, all significantly reduced
infarct size in both mice strains following MI; however, the extent of infarct resorption
was more prominent in the last two groups (Figure 15). Reduction of infarct size upon
TIMP-1 or MMP inhibitor transplantation in the infarcted myocardium has already been
demonstrated (7; 17); however, we are first to report that ES-TIMP-1-CM will provide
similar outcome. Furthermore, the infarct size measured in TIMP-1 KO and C57BL/6
hearts were similar post TIMP-1 delivery even though the extent of infarction was bigger
in the TIMP-1 depleted mice prior to treatment. The efficiency of infarct resorption in
TIMP-1 KO animals treated with TIMP-1 exemplifies its importance in ECM regeneration
and balance.
Extent of infarct size area severely impacted left ventricular contractile ability as
demonstrated by decreased fractional shortening and ejection fraction parameters
measured following MI (Figure 16). Of note, the fractional data collected from TIMP-1
KO animals were expectedly lower than the ones collected from C57BL/6 mice;
however, ejection fraction was affected in the same way for both strains (Figure 16).
The rather unpredicted EF data is in accordance with multiple previously published
works demonstrating exacerbated left ventricular remodeling and decreased FS indices
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in TIMP-1 KO mice following MI, with pseudo-normal to minimally affected ejection
volumes (26). This was attributed to mitral regurgitation which accompanies acute MI in
TIMP-1 KO mice and mitigates volumes measurements (26; 27). Nonetheless, ESTIMP-1-CM and TIMP-1 delivery significantly improved both FS and EF data in the
infarcted heart of both strains.
In conclusion, the present study compared the beneficial effect of direct
intramyocardial delivery of TIMP-1 or ES-TIMP-1-CM in the MI setting. Our data
revealed that both treatments significantly diminish Caspase-3 mediated cardiac
apoptosis and fibrosis (interstitial and vascular) leading to significantly smaller infarct
area and improved contractile function. Improved cardiac function is thought to be the
result of limited cardiac myocytes loss and less collagen deposition within the host
myocardium. Furthermore, we demonstrate that TIMP-1 factor alone is sufficient to
significantly resorb cardiac remodeling in both TIMP-1 KO and control animals and
resume similar cardiac function in both strains regardless of the extent of starting
damage. However, future studies are necessary to identify the mechanisms by which
TIMP-1 prevents adverse cardiac remodeling in the infarcted myocardium and how it
overpasses any other anti-apoptotic anti-fibrotic mechanism provided by other ES cells
released factors.
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Figures

Figure 11. ES-TIMP-1-CM and TIMP-1 blunt apoptosis in the Infarcted Myocardium
of C57BL/6 and TIMP-1 KO mice. TUNEL representative confocal photomicrographs
demonstrating cardiac apoptosis are detailed in Figure 11A for C57BL/6 and Figure 11B
for TIMP-1 KO mice. TUNEL positive nuclei are shown in red (a,d,g,j,and m), total nuclei
stained blue with DAPI (b,e,h,k, and n) and merged TUNEL and DAPI images are
depicted in (c,f,i,l and o). Histogram 11B depicts quantification of percent apoptotic
nuclei against total DAPI for both C57BL/6 and TIMP-1 KO mice. Scale bar= 25µm.
Data was collected from N=6 per group and 1 to 2 sections per animal.*p<0.05. vs
Sham and #p<0.05 vs MI+CC. Brackets over each group means the given significance
above it applies to both strains.
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Figure 12. ES-TIMP-1-CM and TIMP-1 Blunt Caspase-3 Mediated Apoptosis in
Cardiac Myocytes. Figure 12A depicts confocal representative images obtained from
MI-CC animals from C57BL/6 mice (a-f) and TIMP-1 KO (g-l) demonstrating apoptotic
nuclei in red (a and g), Caspase-3 positive cells in yellow (b and h), sarcomeric α-actin
positive cells in green (c and i), and total nuclei in blue (d and j). A merge of four
stainings is depicted in white (e and k) and enlarged areas from e and k images are
presented in f and l respectively. Scale bar= 100µm. Histogram 12B represents
quantitative analysis results of % apoptotic cardiac myocytes over total cardiac
myocytes. Histogram 12B demonstrates Caspase-3 activity assay results for both
strains and their respective treatments. Data was collected from N=5 per group and 1 to
2 sections per animal.*p<0.05. vs Sham and #p<0.05 vs MI+CC. Brackets over each
group means the given significance above it applies to both strains.
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Figure 13. Reduced Interstitial Fibrosis Following ES-TIMP-1-CM and TIMP-1
Transplantation in the Infarcted Myocardium. Figure 13A depicts interstitial fibrosis
(IF) representative images obtained from all study groups per strain; C57BL/6 mice (ae) and TIMP-1 KO animals (f-j). 20x magnification. Histogram 13B shows quantitative
analysis of measured interstitial fibrosis area in C57BL/6 and TIMP-1 KO animals. Data
was collected from N=7 per group.*p<0.05. vs Sham and #p<0.05 vs MI+CC. Brackets
over each group means the given significance above it applies to both strains.
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Figure 14. Reduced Vascular Fibrosis Following ES-TIMP-1-CM and TIMP-1
Transplantation in the Infarcted Myocardium. Figure 14A depicts representative
photomicrographs of vascular fibrosis obtained under a 20x objective of bright field
Olympus microscope. C57BL/6 mice are in (a-e) and TIMP-1 KO animals are in (f-j).
Figure 14B shows %vascular fibrosis per vascular area quantified on C57BL/6 and
TIMP-1 KO animals. Data was collected from N=7 per group.*p<0.05. vs Sham and
#p<0.05 vs MI+CC. Brackets over each group means the given significance above it
applies to both strains.
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Figure 15. Reduced Infarct Size Following ES-TIMP-1-CM and TIMP-1
Transplantation in the Infarcted Myocardium. Figure 15A shows representative
whole-heart images depicting infarct size from both strains and all corresponding
treatment groups under 2x magnification. Pink color represents healthy cardiac cells,
blue areas represent fibrotic tissue (Infarct area). Histogram 15B shows quantification
analysis of % infarct size in both C57BL/6 and TIMP-1 KO mice and their respective
treatments. Data was collected from N=7 per group.*p<0.05. vs Sham and #p<0.05 vs
MI+CC. Brackets over each group means the given significance above it applies to both
strains.
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Figure 16. Improved Heart Function Following ES-TIMP-1-CM and TIMP-1
Transplantation in the Infarcted Myocardium. Results of echocardiography analysis
D14 post-surgery are presented in Figure 16. Table 16A summarizes quantitative data
for % fractional shortening (FS) and ejection fraction (EF) parameters from all groups
measured in both C57BL/6 and TIMP-1 KO mice. Histogram 16B represents FS%
quantitative data in both stains and histogram 16C depicts %EF values obtained from
both stains and all five treatment groups. (p<0.05, Figure 16). Data was collected from
n=6-8 animals per group. *p<0.05 vs Sham, #p<0.05 vs MI+CC and $ p<0.05 vs
MI+ESCM. Brackets over each group means the given significance above it applies to
both strains.
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CHAPTER FIVE: DISCUSSION
Cell transplantation therapy for cardiac repair following MI has shown timid
benefits given the limited survival and plasticity of transplanted cells (1; 2). Therefore,
boosting endogenous CSCs populations to promote cardiac regeneration is necessary
to promote sufficient myocardium repair. Tremendous efforts have been put in place to
identify existent pools of endogenous CSCs (2; 3; 15; 21). Results from these studies
demonstrate that following injury, CSCs proliferate and differentiate in an attempt to
repair the damaged organ; however, the differentiation rate of these cells remains
disproportionate as compared to the extent of cell loss (2; 3; 15; 21; 25). Therefore,
identifying factors that can promote sufficient CSCs differentiation into cardiac myocyte,
VSM and ECs to replace lost cells and regain pre-MI homeostasis is at the forefront of
cardiac regenerative research.
TIMP-1 is a protease inhibitor expressed in the ECM of many tissues including
the myocardium to control MMPs-mediated aberrant collagen deposition (4; 5; 14).
Additionally, it has been linked to multiple cellular processes including enhanced cell
proliferation and inhibition of apoptosis (5; 19; 20; 26). However, the ability of TIMP-1 to
promote CSC proliferation and differentiation has not been established. In our
previously published work, we engineered ES-TIMP-1 cells and transplanted them into
the infarcted murine heart (14). Collected data demonstrated improved contractile
function resulting at least in part from TIMP-1 enhancing transplanted ES cell
engraftment, survival, and differentiation into cardiac myocytes (14). Therefore, we
postulated that TIMP-1 released by ES-TIMP-1 cells may have further activated
endogenous cardiac stem cells (CSCs) that express TIMP-1 receptor (CD63) leading to
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indigenous cardiac regeneration therefore contributing to the reported improvement in
cardiac function post MI injury.
In this regard, our first study (Chapter 2) aimed at identifying a sub-population of
CSCs expressing CD63 and c-kit markers from isolated murine CSCs. We verified that
TIMP-1 treatment enhances CD63+ve/c-kit+ve CSCs proliferation and differentiation into
cardiac myocytes, VSM cells and ECs in vitro. Finally, we provided evidence that TIMP1 induces CD63+ve/c-kit+ve CSCs differentiation through enhancing cardiac genes
(GATA-4, Mef2C and Nkx-2.5) expression.
Our in vitro data established that 60% of isolated c-kit+ve CSCs were CD63+ve/ckit+ve and ES-TIMP-1-CM and TIMP-1 treatments significantly increased their
proliferation rate. As previously mentioned in chapter 2, CD63 receptor is expressed in
multiple cell types; however, we are first to report its expression by CSCs. Furthermore,
enhanced CSCs proliferation mediated through TIMP-1/CD63 axis, demonstrated in this
first study, is in accordance with previously published work on hMSCs which showed
enhanced stem cell proliferation upon TIMP-1 binding CD63 on the cell surface (12).
Next, we investigated whether TIMP-1 could promote significant CD63+ve/c-kit+ve
CSC differentiation in vitro. Multiple factors released in the ES media have been shown
to promote cardiac differentiation such as IGF1/2, bone morphogenetic protein-2 (BMP2), platelet-derived growth factor (PDGF) and VEGF (27; 28). However, the extent of
cardiac differentiation is insufficient to restore pre-MI capacity (2; 21; 27; 28). Of note,
TIMP-1 role in cell differentiation has been previously reported on germinal center B
cells and oligodendrocyte (23). Its involvement in cardiac differentiation, however, has
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not yet been established. In the present study, we are first to report that TIMP-1
enhances cardiac differentiation by targeting a unique CSC population, CD63+ve/c-kit+ve.
To

further

delineate

the

mechanism

mediating

CD63+ve/c-kit+ve

CSC

differentiation upon TIMP-1 treatment, we measured cardiac gene expression on
isolated CSCs. GATA-4, Mef2C and Nkx-2.5 are cardiogenic factors expressed by stem
cells undergoing cardiac differentiation (8-11; 31). Particularly, GATA-4 and Nkx-2.5 are
indicative of myocyte differentiation while Mef2C is expressed in both cardiac myocyte
and vascular differentiating cells (8-11; 31). Our collected data demonstrated that TIMP1 binding to its receptor expressed on CD63+ve/c-kit+ve CSCs surface triggers a
downstream pathway which leads to enhanced cardiac genes expression resulting in
CD63+ve/c-kit+ve CSCs differentiation. However, the intermediate signaling mechanism
determining the differentiation fate of CSCs upon CD63 activation has not been the
focus of this study and therefore remains to be elucidated.
Taken together, our first study (Chapter 2) establishes the existence of a
CD63+ve/c-kit+ve CSC population that is susceptible to proliferate and differentiate into
cardiac myocytes and vascular cells in vitro upon treatment with TIMP-1. Furthermore,
we show that TIMP-1/CD63 interaction leads to enhanced expression of GATA-4,
Mef2C and Nkx-2.5 genes leading to enhanced cardiac differentiation.
We conclude our first study (Chapter 2) by highlighting the need for additional
experiments aiming at identifying CD63+ve/c-kit+ve CSCs in vivo, their localization in
respect to the infarct zone and their ability to migrate, proliferate and differentiate upon
TIMP-1 transplantation. Additionally, identifying the molecular mechanisms promoting
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their proliferation and differentiation could provide more insight on how these cells could
be best taken advantage of in the clinical set up.
In study 2 (Chapter 3), we aimed at addressing the above highlighted points by
performing MI surgery on TIMP-1 KO and C57BL/6 mice followed by intramyocardial
delivery of ESCM, ES-TIMP-1-CM or recombinant TIMP-1 protein. These three groups
were done to emphasize the effect of TIMP-1 over any other factors released by stem
cells present in the CM. We stipulated that TIMP-1 alone would be sufficient to activate
CD63+ve/c-kit+ve CSCs and regenerate the damaged myocardium. Our collected data
from study 2 demonstrate existence of CD63+ve/c-kit+ve CSCs population in the peri
infarct heart. Futheremore, we provide evidence that intramyocardial delivery of ESTIMP-1-CM or TIMP-1 equivalently enhance CD63+ve/c-kit+ve CSCs proliferation and
differentiation into cardiac myocytes, ECs and VSM cells, and promote additional CD63
expression in the heart. Most importantly, this study for the first time demonstrates that
endogenous TIMP-1 is necessary for CD63 expression on CD63+ve/c-kit+ve CSCs. This
novel role of TIMP-1 was evidenced by the drastic reduction in CD63 expression
resulting in decreased number of CD63+ve/c-kit+ve CSCs population in TIMP-1 KO
animals compared to control mice. Moreover, exogenous delivery of TIMP-1 was
sufficient to rebound CD63 expression and replenish CD63+ve/c-kit+ve CSCs pool in
TIMP-1 KO animals.
Next, we aimed at identifying the downstream mechanism governing CD63+ve/ckit+ve CSCs proliferation and differentiation upon TIMP-1 treatment. Stem cell
differentiation is traditionally mediated through the canonical Wnt/β-catenin pathway;
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however, our data from study 2 demonstrate CD63+ve/c-kit+ve activation bypasses Wnt
but requires CD63 and β-catenin intermediates (6; 17; 18).

Activation of the non-

canonical CD63/β-catenin pathway is suggested by increased CD63, β-catenin and
phospho-β-catenin expression in MI hearts treated with ES-TIMP-1-CM and TIMP-1
when compared to non-treated animals. We therefore postulated that TIMP-1 treatment
activates CD63 which induces dephosphorylation of Axin complex, preventing β-catenin
ubiquitination and degradation. Released β-catenin then accumulates in the cytoplasm
and is phosphorylated prior to nucleus translocation.

β-catenin thereafter induces

cardiac gene expression and promotes cardiac proliferation and differentiation as
previously reported (6; 17; 18). We additionally stipulated that endogenous TIMP-1
activates CD63/β-catenin on CD63+ve/c-kit+ve CSCs promoting additional CD63
expression. Our results are in accordance with multiple studies demonstrating ES cells
differentiate into cardiac cells through activation of β-catenin pathway and subsequent
expression of cardiac genes, such as; Nkx2.5, GATA-4, Mef2C, β-myosin heavy chain
(β-MHC) and cardiac troponin T (cTnT) (6; 9; 11; 31).
In the present study, we choose to identify c-kit+ve CSCs population because of
their prevalence in the heart. However, other CSCs exist such as side population (SP)
cells, cardiac progenitor cells (CPCs), Sca-1+ve cells, cardio sphere cells and Isl1+ve cells
which are less abundant and less characterized (2; 15; 21; 22; 25). It is therefore
imperative to identify the relative contribution of CD63+ve CSCs that are not c-kit+ve in
cardiac regeneration following MI.
In conclusion for study 2, we provide evidence for the existence of a CSC
population, CD63+ve/c-kit+ve, within the peri-infarct area of the murine heart. We show
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that these cells can be triggered to differentiate into cardiac cells by exogenous delivery
of TIMP-1 factor or ES-TIMP-1-CM. Finally, we demonstrate that CD63+ve/c-kit+ve CSCs
activation is mediated through non-canonical CD63/β-catenin pathway.
Besides the regenerative role identified in study 1 and 2, TIMP-1 is known to
alleviate cardiac remodeling through inhibition of MMPs; however, not much is known
about the molecular mechanism mediating this protective effect and whether other
factors released in ESCM would provide a better protection (7; 16; 29). In study 3
(Chapter 4), we compared the anti-cardiac remodeling effect of direct transplantation of
TIMP-1 protein, ESCM, and ES-TIMP-1-CM in the MI heart of both C57BL/6 and TIMP1 KO mice. We hypothesized that parallel to enhancing cardiac proliferation and
differentiation, TIMP-1 will surpass ESCM in blunting apoptosis and fibrosis in the MI
heart.
Our previously published data demonstrated ES-TIMP-1 cell delivery in the MI
heart decreased Caspase-3 mediated apoptosis, however, whether this effect is
mediated through TIMP-1 or other factors additionally released by ES-TIMP-1 cells was
not clear . Within study 3, we provide evidence that TIMP-1 alone is sufficient to
decrease overall cardiac apoptosis and specifically blunt Caspase-3 activity (an intrinsic
mediator of apoptosis) in cardiac myocytes following MI. Furthermore, TIMP-1 KO
animals showed significantly higher Caspase-3 activity in cardiac myocytes compared
to control mice following MI which further establishes that TIMP-1 acts as a shield
against cardiac myocytes apoptosis through inhibition of Caspase-3 activity.
One of the hallmarks of cardiac remodeling is fibrosis, which results from
collagen deposition in the interstitial and vascular spaces leading to stiffening of the left
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ventricle, thereafter hindering its contractile capacity (7; 24; 29; 30). MMPs are well
documented fibrosis mediators which function is predominantly controlled by TIMP-1(7;
24; 29; 30). Our previously published work showed ES-TIMP-1 cells transplantation in
the MI heart decreased overall interstitial and vascular fibrosis . However, it was unclear
whether the anti-fibrotic effect was the result of TIMP-1 alone or other factors
additionally released in ES-TIMP-1-CM. To address this question, we measured
interstitial and vascular fibrosis on TIMP-1 KO and C57BL/6 infarcted hearts following
ESCM, ES-TIMP-1-CM and TIMP-1 treatments. Our data showed that although all
treatments were efficient at blunting fibrosis (interstitial and vascular); the last two
treatments provided the best outcome regardless of the strain. Of note, hepatic growth
factor (HGF), an ES cell-released factor present in their media and previously linked to
decreased fibrosis in lung alveolar epithelium, might additionally be responsible for the
deceased fibrosis reported in our ESCM hearts (13) . However, TIMP-1 seems to
provide a stronger anti-fibrotic effect as demonstrated by the extent of fibrosis decrease
we report following TIMP-1 treatment compared with any other combined factors
released by ES cells.
Finally, as part of study 3, we investigated the impact of TIMP-1 on infarct size
measurements and left ventricular contractile function. Expectedly, our results were in
accordance with previous work demonstrating larger infarct areas in TIMP-1 KO animals
compared with their C57BL/6 counterparts two weeks following MI (7; 16). Moreover,
infarct size measurements were significantly lower in ES-TIMP-1-CM and TIMP-1
treatments as compared to either ESCM or non-treated animals. Furthermore, we are
first to report that TIMP-1 anti-fibrotic effect is more efficient than any combined effects
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from factors released by ES-TIMP-1 cells. Finally, we show that exogenous delivery of
TIMP-1 is able to salvage equivalent amount of myocardium in TIMP-1 KO and
C57BL/6 hearts even though the extent of infarction was bigger in TIMP-1 depleted
mice prior to treatment.
Functional data is greatly impacted by the extent of cardiac cell death and fibrotic
tissue accumulation following MI. In fact, the larger the infarct size, the lower the ability
of the ventricle to efficiently pump (7; 16). This in part explains why FS percent in TIMP1 KO animals were lower than C57BL/6 mice. Surprisingly though, EF data which reflect
the amount of blood pumped out within every single contraction was similar in both
strains. In other words, although infarct measurements and FS data were drastically
lower in TIMP-1 KO infarcted hearts compared to C57BL/6 mice, volume measurements
between both strains were apparently not affected.

To justify this observation, we

postulated that mitral regurgitation which occurs in severely affected MI hearts and
TIMP-1 KO animals for instance might have mitigated volume measurements in TIMP-1
KO animals leading to pseudo normal EF numbers regardless to their dramatic left
ventricular remodeling (7). Nonetheless, ES-TIMP-1-CM and TIMP-1 delivery
significantly improved both FS and EF data in the infarcted heart of both strains.
In conclusion, study 3 (Chapter 4) compared the beneficial effect of
intramyocardial delivery of TIMP-1 or ES-TIMP-1-CM in the MI setting. Our data
revealed that both treatments significantly diminish Caspase-3 mediated cardiac
apoptosis, and reduce vascular and interstitial fibrosis leading to significantly smaller
infarct sizes and improved contractile function in both control and TIMP-1 KO animals.
Furthermore, we demonstrated that exogenous delivery of TIMP-1 factor can sufficiently
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reduce cardiac remodeling in both TIMP-1 KO and control animals which resume similar
cardiac function. In the current study, we stipulate that the anti-apoptotic and anti-fibrotic
role of TIMP-1 in the heart is most likely mediated through CD63 receptor expressed on
cardiac cells which most likely differentiated from CD63 +ve/c-kit+ve CSCs previously
identified in study 1 and 2. Nonetheless, future studies are warranted to verify this
hypothesis.
Overall, study 1, 2 and 3 demonstrate that CD63+ve/c-kit+ve cells are a novel CSC
population present in the peri-infarct area of the heart. When treated with TIMP-1 both
in vitro and in vivo, CD63+ve/c-kit+ve CSCs showed 1) increased proliferation compared
to control cells, 2) enhanced CD63 expression, 3) significantly improved cardiac
myocyte, VSM cell, and EC differentiation, 4) increased cardiac gene (GATA-4, Mef2C,
and Nkx-2.5) expression, 5) CD63+ve/c-kit+ve

differentiation is mediated through

CD63/β-catenin pathway, and 6) TIMP-1 inhibits apoptosis and fibrosis and improves
contractile function following myocardial transplantation. Our data provided in the 3
studies demonstrate for the first time the multi-faceted role of TIMP-1. This molecule
has a strong regenerative potential through activation of endogenous CD63+ve/c-kit+ve
CSCs while alleviating adverse cardiac remodeling consecutive to MI, therefore opening
a new era for cardiac regeneration research.
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